≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

Brain astrocytoma, helper endpoint

Endpoint Browser

HLP_C3_ASTROCYTOMA

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cancer registry: Topography ICD-O-3 — C71
  • Cancer registry: Morphology ICD-O-3 — 9400
  • Cancer registry: Behaviour codes — 3

1 out of 7 registries used, show all original rules.

166

4. Check minimum number of events

None

166

5. Include endpoints

None

166

6. Filter based on genotype QC (FinnGen only)

161

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
C
First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 161 80 81
Unadjusted period prevalence (%) 0.03 0.03 0.04
Median age at first event (years) 39.95 38.20 41.68

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
166
Matched controls
1660
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
575.3
276.3
129
10
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
136.4
218.5
128
40
130
Kela drug reimbursment
Malignant tumour
129.5
215.0
135
54
N03AX14
ATC
levetiracetam; systemic
137.6
192.0
102
19
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
146.2
177.9
92
14
L01AX03
ATC
temozolomide; systemic
753.7
149.6
127
7
H02AB02
ATC
dexamethasone; systemic
49.7
149.5
124
93
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
48.6
147.8
124
95
A04AA02
ATC
granisetron; systemic, transdermal
51.5
141.1
95
42
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
106.2
123.0
65
10
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
42.5
105.5
70
28
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
73.8
103.5
58
12
WF002
NOMESCO Finland
Radical radiotherapy
37.4
99.5
69
31
C71.11
ICD-10 Finland
Malignant tumor of frontal lobe grade II glioma
792.4
90.4
81
*
N03AF02
ATC
oxcarbazepine; oral
29.6
82.0
61
32
9400/3-C71.1
ICD-O-3
Astrocytoma, NOS, of frontal lobe
+∞
68.6
61
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
23.0
67.2
55
35
R56.8
ICD-10 Finland
Other and unspecified convulsions
19.8
65.8
59
45
A03FA01
ATC
metoclopramide; systemic, rectal
13.6
65.3
112
220
WF003
NOMESCO Finland
Adjuvant radiotherapy
32.9
64.2
44
18
C71.10
ICD-10 Finland
Malignant tumor in frontal lobe without histology
163.0
61.9
62
6
D43.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, supratentorial
190.7
61.8
61
5
9400/3-C71.9
ICD-O-3
Astrocytoma, NOS, of brain, NOS
+∞
58.9
53
*
XA800
NOMESCO Finland
Neuropsychological investigation
17.3
56.9
54
45
C71.21
ICD-10 Finland
Malignant tumor of temporal lobe grade II glioma
+∞
56.5
51
*
A04AA01
ATC
ondansetron; systemic, rectal
14.8
54.6
58
58
ZXC95
NOMESCO Finland
Use of surgical navigator
107.2
54.2
57
8
G40.9
ICD-10 Finland
Epilepsy, unspecified
27.1
52.1
38
18
AA1AD
NOMESCO Finland
CT of head and brain
10.4
51.7
111
269
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
278.7
43.1
42
*
Z51.5
ICD-10 Finland
Palliative care
13.7
42.4
45
44
XX3DW
NOMESCO Finland
Time consuming IT work
9.6
40.6
60
92
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
9.2
40.6
64
106
C71.20
ICD-10 Finland
Malignant tumor in temporal lobe without histology
+∞
39.1
36
*
N03AX18
ATC
lacosamide; systemic
78.6
33.7
37
6
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
7.4
33.3
64
129
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
106.2
32.1
34
*
9400/3-C71.2
ICD-O-3
Astrocytoma, NOS, of temporal lobe
+∞
31.2
29
*
C71.1
ICD-10 Finland
Malignant neoplasm: Frontal lobe
+∞
26.8
25
*
AAG00
NOMESCO Finland
Stereotactic intracranial biopsy
306.0
26.5
26
*
C71.12
ICD-10 Finland
Malignant tumor of frontal lobe grade III glioma
106.8
25.5
27
*
C71.2
ICD-10 Finland
Malignant neoplasm: Temporal lobe
292.2
25.4
25
*
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
49.6
24.5
29
7
ZXC40
NOMESCO Finland
Use of ultrasound
64.0
23.9
27
5
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
265.1
23.2
23
*
WX882
NOMESCO Finland
High dependency care
34.7
22.8
29
10
WX872
NOMESCO Finland
Intensive care
10.4
21.8
26
29
C71.90
ICD-10 Finland
Malignant tumor in unspecified localization in the brain without histology
+∞
20.2
19
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
36.4
19.9
25
8
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
17.0
19.5
31
22
D43.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Central nervous system, unspecified
79.5
19.2
21
*
C71.22
ICD-10 Finland
Malignant tumor of temporal lobe grade III glioma
+∞
19.1
18
*
N03AB02
ATC
phenytoin; systemic
37.8
18.5
23
7
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
200.5
17.9
18
*
WZC00
NOMESCO Finland
Treatment plan or consultation
4.0
17.6
98
437
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
35.9
17.5
22
7
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
56.4
17.4
20
*
C71.31
ICD-10 Finland
Malignant tumor of the parietal lobe grand II glioma
+∞
17.0
16
*
N03AG01
ATC
valproic acid; systemic, rectal
6.1
16.0
31
60
YX8VG
NOMESCO Finland
Stereotactic MRI exmaination with high intensity magnet for dose design of radiotherapy
94.2
15.9
17
*
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
175.9
15.8
16
*
N03AF01
ATC
carbamazepine; oral, rectal
7.9
15.7
23
33
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
62.7
15.1
17
*
A02BC02
ATC
pantoprazole; systemic
4.5
14.7
134
798
N05BA09
ATC
clobazam; oral
30.4
14.6
19
7
C71.23
ICD-10 Finland
Malignant tumor of temporal lobe grade IV glioma
+∞
13.7
13
*
C71.29
ICD-10 Finland
Malignant tumor in temporal lobe other or unspecified histology
151.9
13.7
14
*
R4150
NOMESCO Finland
Neuropsychological rehabilitation
18.7
13.4
20
12
ZX050
NOMESCO Finland
Stereotactic radiotherapy
54.5
13.1
15
*
N05CD08
ATC
midazolam; nasal, systemic
17.3
13.0
20
13
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
6.7
13.0
22
37
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
35.1
12.8
16
5
YX8BD
NOMESCO Finland
Stereotactic extensive CT examination for dose design of radiotherapy
75.8
12.8
14
*
G40.10
ICD-10 Finland
Simple partial seizures
75.8
12.8
14
*
WZC30
NOMESCO Finland
Teaching
3.8
12.1
46
153
WX402
NOMESCO Finland
General anaesthesia
3.4
12.1
61
244
WC105
NOMESCO Finland
Simple cytostatic therapy of local tumor recidive
70.0
11.8
13
*
C71.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of brain
70.0
11.8
13
*
ZXE20
NOMESCO Finland
More than three and less than five hours
4.3
11.7
34
93
C71.13
ICD-10 Finland
Malignant tumor of frontal lobe grade IV glioma
+∞
11.6
11
*
C71.81
ICD-10 Finland
Overall malignant tumor of the brain grade II glioma
+∞
11.6
11
*
C71.01
ICD-10 Finland
Malignant tumor of cerebellum except lobes and ventricles grade II glioma
128.6
11.6
12
*
C71.19
ICD-10 Finland
Malignant tumor of frontal lobe other or unspecified histology
128.6
11.6
12
*
ZXM40
NOMESCO Finland
Use of fluorescent substance
128.6
11.6
12
*
C71.30
ICD-10 Finland
Malignant tumor in parietal lobe without histology
128.6
11.6
12
*
N03AX23
ATC
brivaracetam; systemic
128.6
11.6
12
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.2
10.8
58
239
H53.4
ICD-10 Finland
Visual field defects
13.3
10.6
18
15
AAA10
NOMESCO Finland
Biopsy through craniotomy
+∞
10.5
10
*
WF029
NOMESCO Finland
Radiotherapy of local residive tumor
35.0
10.5
13
*
183
Kela drug reimbursment
Lamotrigin and topiramate
16.3
9.7
15
10
9400/3-C71.0
ICD-O-3
Astrocytoma, NOS, of cerebrum
+∞
9.5
9
*
C71.99
ICD-10 Finland
Malignant tumor in unspecified localization in the brain other or unspecified histology
39.0
9.1
11
*
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
39.0
9.1
11
*
G91.1
ICD-10 Finland
Obstructive hydrocephalus
94.7
8.5
9
*
H02AB09
ATC
hydrocortisone; systemic
10.3
8.5
16
17
H02AB04
ATC
methylprednisolone; systemic
3.7
8.4
30
94
N76
ICPC
Neoplasm nervous system unspecified
+∞
8.4
8
*
XX9BW
NOMESCO Finland
Submitting image material and/or investigation material to authority or other institution
15.5
8.4
13
9
D43.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, unspecified
35.2
8.2
10
*
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
14.0
8.0
13
10
N02AA05
ATC
oxycodone; systemic
3.2
8.0
37
137
AAF05
NOMESCO Finland
Ventriculoperitoneal shunt
26.4
7.7
10
*
D43.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, infratentorial
83.7
7.5
8
*
C71.00
ICD-10 Finland
Malignant tumor of the cerebrum except lobes and ventricles without histology
83.7
7.5
8
*
C71.80
ICD-10 Finland
Overall malignant tumor of the brain without histology
+∞
7.3
7
*
9400/3-C71.3
ICD-O-3
Astrocytoma, NOS, of parietal lobe
+∞
7.3
7
*
R47.0
ICD-10 Finland
Dysphasia and aphasia
21.1
7.2
10
5
A28
ICPC
Limited function/disability NOS
3.3
6.9
28
95
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
10.0
6.9
13
14
AA1BD
NOMESCO Finland
Extensive CT of head and brain
8.4
6.8
14
18
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
13.0
6.7
11
9
N03AX09
ATC
lamotrigine; oral
3.9
6.5
20
56
G40.89
ICD-10 Finland
Other epilepsy
72.5
6.5
7
*
D33.00
ICD-10 Finland
Medial pilosytic astrocytoma of the cerebrum
72.5
6.5
7
*
ZSA00
NOMESCO Finland
Procedure related to previous procedure classified in chapter A
27.8
6.3
8
*
C71.82
ICD-10 Finland
Overall malignant tumor of the brain grade III glioma
+∞
6.3
6
*
C71.32
ICD-10 Finland
Malignant tumor of parietal lobe grade III glioma
+∞
6.3
6
*
C71.40
ICD-10 Finland
Malignant tumor of the occipital lobe without histology
+∞
6.3
6
*
AA5NK
NOMESCO Finland
Tractography within white matter of central nervous system
+∞
6.3
6
*
C71.91
ICD-10 Finland
Malignant tumor in unspecified location in the brain grade II glioma
+∞
6.3
6
*
2151
FHL
Resection, big brain
+∞
6.3
6
*
G40
ICD-10 Finland
Epilepsy
13.2
6.2
10
8

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Neurology
13 [38004458]
-5.2e-01
2.5e+00
4.5e+00
—
4.9e+00
4.8e+00
4.3e+00
cases:4.82%
controls:7.88%
cases:32.53%
controls:3.88%
cases:46.39%
controls:0.97%
—
—
cases:39.39%
controls:0.49%
cases:80.00%
controls:3.28%
cases:86.26%
controls:7.65%
8
130
158
1520
54
64
112
1586
77
16
89
1634
—
65
8
100
1641
128
54
32
1591
113
117
18
1412
Neurosurgery
14 [38004459]
-1.0e+50
3.6e+00
—
1.0e+50
5.5e+00
6.2e+00
4.5e+00
cases:0.00%
controls:1.64%
cases:15.66%
controls:0.48%
—
—
cases:26.51%
controls:0.00%
cases:42.42%
controls:0.30%
cases:77.50%
controls:0.73%
cases:49.62%
controls:1.05%
0
27
166
1623
26
8
140
1642
—
44
0
122
1650
70
5
95
1644
124
12
36
1633
65
16
66
1513
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
-1.5e-01
4.5e-01
3.1e+00
4.9e+00
3.3e+00
1.4e+00
6.5e-01
cases:27.11%
controls:30.24%
cases:30.12%
controls:21.52%
cases:47.59%
controls:4.12%
cases:33.73%
controls:0.36%
cases:52.12%
controls:3.76%
cases:53.75%
controls:23.04%
cases:60.31%
controls:44.34%
45
499
121
1151
50
355
116
1295
79
68
87
1582
56
6
110
1644
86
62
79
1587
86
379
74
1266
79
678
52
851
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
-5.3e-01
1.1e+00
4.8e+00
—
4.4e+00
2.1e+00
8.1e-01
cases:6.63%
controls:10.73%
cases:16.87%
controls:6.12%
cases:39.16%
controls:0.55%
—
—
cases:38.18%
controls:0.79%
cases:34.38%
controls:6.02%
cases:31.30%
controls:16.87%
11
177
155
1473
28
101
138
1549
65
9
101
1641
—
63
13
102
1636
55
99
105
1546
41
258
90
1271
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
-1.6e-01
4.4e-01
3.1e+00
4.8e+00
3.3e+00
1.3e+00
4.9e-01
cases:27.11%
controls:30.42%
cases:30.12%
controls:21.70%
cases:47.59%
controls:4.12%
cases:30.12%
controls:0.36%
cases:50.91%
controls:3.82%
cases:53.13%
controls:23.16%
cases:56.49%
controls:44.28%
45
502
121
1148
50
358
116
1292
79
68
87
1582
50
6
116
1644
84
63
81
1586
85
381
75
1264
74
677
57
852
Medical Oncology
90 [38004507]
—
—
—
—
3.2e+00
4.8e+00
3.9e+00
—
—
—
—
—
—
—
—
cases:22.42%
controls:1.15%
cases:75.63%
controls:2.55%
cases:62.60%
controls:3.40%
—
—
—
—
37
19
128
1630
121
42
39
1603
82
52
49
1477
oxcarbazepine; oral
N03AF02 [21604418]
—
3.5e+00
1.0e+50
—
—
4.4e+00
4.0e+00
—
—
cases:9.04%
controls:0.30%
cases:11.45%
controls:0.00%
—
—
—
—
cases:25.63%
controls:0.43%
cases:25.95%
controls:0.65%
—
15
5
151
1645
19
0
147
1650
—
—
41
7
119
1638
34
10
97
1519
Complex partial epileptic seizure with secondary generalization
G40.22 [2000502141]
—
2.6e+00
—
1.0e+50
—
4.7e+00
4.5e+00
—
—
cases:4.82%
controls:0.36%
—
—
cases:3.61%
controls:0.00%
—
—
cases:25.00%
controls:0.30%
cases:32.06%
controls:0.52%
—
8
6
158
1644
—
6
0
160
1650
—
40
5
120
1640
42
8
89
1521
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
—
1.0e+00
4.2e+00
1.0e+50
4.1e+00
1.9e+00
9.6e-01
—
—
cases:6.63%
controls:2.48%
cases:21.69%
controls:0.42%
cases:3.01%
controls:0.00%
cases:15.15%
controls:0.30%
cases:15.63%
controls:2.67%
cases:16.03%
controls:6.80%
—
11
41
155
1609
36
7
130
1643
5
0
161
1650
25
5
140
1644
25
44
135
1601
21
104
110
1425
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-3.7e-01
3.1e-01
2.6e+00
3.5e+00
3.3e+00
1.4e+00
3.3e-01
cases:24.70%
controls:32.12%
cases:25.90%
controls:20.42%
cases:38.55%
controls:4.61%
cases:12.05%
controls:0.42%
cases:49.70%
controls:3.64%
cases:51.25%
controls:19.82%
cases:50.38%
controls:42.18%
41
530
125
1120
43
337
123
1313
64
76
102
1574
20
7
146
1643
82
60
83
1589
82
326
78
1319
66
645
65
884
Outpatient Hospital
22 [8756]
-2.8e-01
7.1e-01
3.6e+00
1.0e+50
3.9e+00
2.1e+00
1.1e+00
cases:18.07%
controls:22.61%
cases:11.45%
controls:6.00%
cases:25.30%
controls:0.91%
cases:12.65%
controls:0.00%
cases:22.42%
controls:0.61%
cases:26.25%
controls:4.26%
cases:24.43%
controls:10.14%
30
373
136
1277
19
99
147
1551
42
15
124
1635
21
0
145
1650
37
10
128
1639
42
70
118
1575
32
155
99
1374
Inpatient Hospital
21 [8717]
-2.6e-01
8.8e-01
3.5e+00
1.0e+50
3.4e+00
1.9e+00
8.0e-01
cases:24.10%
controls:29.21%
cases:18.67%
controls:8.67%
cases:31.93%
controls:1.45%
cases:13.86%
controls:0.00%
cases:27.88%
controls:1.21%
cases:32.50%
controls:6.99%
cases:30.53%
controls:16.55%
40
482
126
1168
31
143
135
1507
53
24
113
1626
23
0
143
1650
46
20
119
1629
52
115
108
1530
40
253
91
1276
Platelets [#/volume] in Blood
26515-7 [3007461]
-1.4e-01
2.5e-01
2.4e+00
4.3e+00
2.7e+00
9.6e-01
2.8e-01
cases:37.95%
controls:41.27%
cases:37.95%
controls:32.24%
cases:47.59%
controls:7.45%
cases:30.12%
controls:0.61%
cases:54.55%
controls:7.22%
cases:58.13%
controls:34.77%
cases:65.65%
controls:59.06%
63
681
103
969
63
532
103
1118
79
123
87
1527
50
10
116
1640
90
119
75
1530
93
572
67
1073
86
903
45
626
MCH [Entitic mass]
28539-5 [3035941]
-1.7e-01
2.5e-01
2.4e+00
4.3e+00
2.7e+00
9.5e-01
2.8e-01
cases:37.35%
controls:41.39%
cases:37.95%
controls:32.24%
cases:47.59%
controls:7.45%
cases:30.12%
controls:0.61%
cases:54.55%
controls:7.28%
cases:58.13%
controls:34.95%
cases:65.65%
controls:59.19%
62
683
104
967
63
532
103
1118
79
123
87
1527
50
10
116
1640
90
120
75
1529
93
575
67
1070
86
905
45
624
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-1.7e-01
2.5e-01
2.4e+00
4.3e+00
2.7e+00
9.5e-01
2.8e-01
cases:37.35%
controls:41.45%
cases:37.95%
controls:32.24%
cases:47.59%
controls:7.45%
cases:30.12%
controls:0.61%
cases:54.55%
controls:7.28%
cases:58.13%
controls:34.95%
cases:65.65%
controls:59.19%
62
684
104
966
63
532
103
1118
79
123
87
1527
50
10
116
1640
90
120
75
1529
93
575
67
1070
86
905
45
624
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-1.5e-01
2.5e-01
2.4e+00
4.3e+00
2.7e+00
9.5e-01
2.8e-01
cases:37.95%
controls:41.45%
cases:37.95%
controls:32.24%
cases:47.59%
controls:7.45%
cases:30.12%
controls:0.61%
cases:54.55%
controls:7.28%
cases:58.13%
controls:34.95%
cases:65.65%
controls:59.12%
63
684
103
966
63
532
103
1118
79
123
87
1527
50
10
116
1640
90
120
75
1529
93
575
67
1070
86
904
45
625
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-1.5e-01
2.5e-01
2.4e+00
4.3e+00
2.7e+00
9.5e-01
2.7e-01
cases:37.95%
controls:41.64%
cases:37.95%
controls:32.30%
cases:47.59%
controls:7.45%
cases:30.12%
controls:0.61%
cases:54.55%
controls:7.28%
cases:58.13%
controls:35.02%
cases:65.65%
controls:59.25%
63
687
103
963
63
533
103
1117
79
123
87
1527
50
10
116
1640
90
120
75
1529
93
576
67
1069
86
906
45
623
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-1.8e-01
2.5e-01
2.4e+00
4.3e+00
2.7e+00
9.4e-01
2.7e-01
cases:37.35%
controls:41.58%
cases:37.95%
controls:32.24%
cases:47.59%
controls:7.45%
cases:30.12%
controls:0.61%
cases:54.55%
controls:7.28%
cases:58.13%
controls:35.08%
cases:65.65%
controls:59.25%
62
686
104
964
63
532
103
1118
79
123
87
1527
50
10
116
1640
90
120
75
1529
93
577
67
1068
86
906
45
623
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
-1.5e-01
3.3e-01
2.7e+00
3.4e+00
3.0e+00
1.2e+00
4.5e-01
cases:32.53%
controls:35.82%
cases:33.13%
controls:26.24%
cases:47.59%
controls:5.58%
cases:13.25%
controls:0.48%
cases:53.94%
controls:5.58%
cases:56.88%
controls:28.75%
cases:63.36%
controls:52.52%
54
591
112
1059
55
433
111
1217
79
92
87
1558
22
8
144
1642
89
92
76
1557
91
473
69
1172
83
803
48
726
Outpatient Visit
OP [9202]
-6.9e-02
3.3e-01
1.5e+00
3.6e+00
1.7e+00
2.2e+00
1.3e+00
cases:65.06%
controls:66.61%
cases:54.82%
controls:46.61%
cases:37.95%
controls:11.58%
cases:15.66%
controls:0.48%
cases:38.79%
controls:10.67%
cases:88.75%
controls:47.17%
cases:91.60%
controls:74.82%
108
1099
58
551
91
769
75
881
63
191
103
1459
26
8
140
1642
64
176
101
1473
142
776
18
869
120
1144
11
385
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
-7.3e-01
9.1e-01
3.1e+00
—
3.8e+00
1.6e+00
8.8e-01
cases:4.22%
controls:8.36%
cases:12.05%
controls:5.21%
cases:15.06%
controls:0.79%
—
—
cases:22.42%
controls:0.67%
cases:23.75%
controls:5.78%
cases:28.24%
controls:14.06%
7
138
159
1512
20
86
146
1564
25
13
141
1637
—
37
11
128
1638
38
95
122
1550
37
215
94
1314
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-1.5e-01
2.5e-01
2.4e+00
4.2e+00
2.7e+00
9.5e-01
2.8e-01
cases:37.95%
controls:41.52%
cases:37.95%
controls:32.30%
cases:47.59%
controls:7.45%
cases:30.12%
controls:0.67%
cases:54.55%
controls:7.28%
cases:58.13%
controls:35.02%
cases:65.65%
controls:59.19%
63
685
103
965
63
533
103
1117
79
123
87
1527
50
11
116
1639
90
120
75
1529
93
576
67
1069
86
905
45
624
CBC panel - Blood by Automated count
58410-2 [40761511]
-1.1e-01
2.8e-01
2.6e+00
4.0e+00
2.8e+00
6.2e-01
1.6e-01
cases:31.33%
controls:33.82%
cases:27.71%
controls:22.42%
cases:36.14%
controls:3.94%
cases:20.48%
controls:0.48%
cases:40.00%
controls:3.76%
cases:36.88%
controls:23.95%
cases:50.38%
controls:46.30%
52
558
114
1092
46
370
120
1280
60
65
106
1585
34
8
132
1642
66
62
99
1587
59
394
101
1251
66
708
65
821
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
-7.3e-01
7.1e-01
3.1e+00
—
4.0e+00
1.8e+00
1.0e+00
cases:3.61%
controls:7.21%
cases:9.64%
controls:4.97%
cases:13.86%
controls:0.73%
—
—
cases:22.42%
controls:0.55%
cases:24.38%
controls:4.92%
cases:27.48%
controls:12.03%
6
119
160
1531
16
82
150
1568
23
12
143
1638
—
37
9
128
1640
39
81
121
1564
36
184
95
1345
levetiracetam; oral, parenteral
N03AX14 [21604436]
—
—
1.0e+50
—
—
5.3e+00
4.6e+00
—
—
—
—
cases:17.47%
controls:0.00%
—
—
—
—
cases:41.88%
controls:0.36%
cases:44.27%
controls:0.78%
—
—
29
0
137
1650
—
—
67
6
93
1639
58
12
73
1517
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-3.0e-01
2.2e-01
2.2e+00
4.2e+00
2.6e+00
8.1e-01
3.1e-01
cases:26.51%
controls:32.79%
cases:28.31%
controls:24.00%
cases:33.73%
controls:5.58%
cases:27.71%
controls:0.55%
cases:41.21%
controls:4.97%
cases:43.75%
controls:25.78%
cases:51.91%
controls:44.28%
44
541
122
1109
47
396
119
1254
56
92
110
1558
46
9
120
1641
68
82
97
1567
70
424
90
1221
68
677
63
852
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
-2.6e-01
5.5e-01
4.5e+00
1.0e+50
3.6e+00
1.5e+00
6.2e-01
cases:6.02%
controls:7.70%
cases:6.63%
controls:3.94%
cases:27.11%
controls:0.42%
cases:11.45%
controls:0.00%
cases:13.33%
controls:0.42%
cases:14.38%
controls:3.47%
cases:19.08%
controls:11.25%
10
127
156
1523
11
65
155
1585
45
7
121
1643
19
0
147
1650
22
7
143
1642
23
57
137
1588
25
172
106
1357
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
—
—
—
1.0e+50
1.0e+50
4.5e+00
4.9e+00
—
—
—
—
—
—
cases:15.66%
controls:0.00%
cases:10.30%
controls:0.00%
cases:35.63%
controls:0.61%
cases:50.38%
controls:0.78%
—
—
—
26
0
140
1650
17
0
148
1649
57
10
103
1635
66
12
65
1517
dexamethasone; oral, parenteral
H02AB02 [21602730]
-1.0e+50
2.3e+00
—
—
—
4.1e+00
2.7e+00
cases:0.00%
controls:2.06%
cases:10.84%
controls:1.21%
—
—
—
—
—
—
cases:42.50%
controls:1.22%
cases:21.37%
controls:1.77%
0
34
166
1616
18
20
148
1630
—
—
—
68
20
92
1625
28
27
103
1502
Laboratory Visit
OMOP4822461 [32036]
-1.0e-01
4.5e-02
1.8e+00
4.8e+00
2.2e+00
4.5e-01
2.0e-01
cases:45.78%
controls:48.36%
cases:45.78%
controls:44.67%
cases:51.20%
controls:15.03%
cases:50.00%
controls:0.79%
cases:57.58%
controls:13.46%
cases:60.00%
controls:48.94%
cases:70.23%
controls:65.86%
76
798
90
852
76
737
90
913
85
248
81
1402
83
13
83
1637
95
222
70
1427
96
805
64
840
92
1007
39
522
Emergency Room Visit
ER [9203]
-3.2e-01
8.7e-01
2.9e+00
—
2.8e+00
1.7e+00
5.4e-01
cases:27.11%
controls:33.88%
cases:23.49%
controls:11.39%
cases:25.90%
controls:1.82%
—
—
cases:18.79%
controls:1.46%
cases:36.25%
controls:9.18%
cases:32.06%
controls:21.65%
45
559
121
1091
39
188
127
1462
43
30
123
1620
—
31
24
134
1625
58
151
102
1494
42
331
89
1198
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
-2.8e-02
1.6e-01
1.8e+00
2.7e+00
2.2e+00
1.2e+00
4.7e-01
cases:33.13%
controls:33.76%
cases:27.11%
controls:24.12%
cases:23.49%
controls:4.79%
cases:4.22%
controls:0.30%
cases:28.48%
controls:4.31%
cases:53.75%
controls:26.02%
cases:63.36%
controls:51.99%
55
557
111
1093
45
398
121
1252
39
79
127
1571
7
5
159
1645
47
71
118
1578
86
428
74
1217
83
795
48
734
pantoprazole; oral, parenteral
A02BC02 [21600097]
-1.4e-01
7.2e-01
2.5e+00
—
3.1e+00
2.2e+00
6.2e-01
cases:12.05%
controls:13.58%
cases:13.25%
controls:6.91%
cases:12.65%
controls:1.15%
—
—
cases:25.45%
controls:1.52%
cases:41.25%
controls:6.99%
cases:28.24%
controls:17.53%
20
224
146
1426
22
114
144
1536
21
19
145
1631
—
42
25
123
1624
66
115
94
1530
37
268
94
1261
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
-2.4e-01
2.2e+00
3.5e+00
—
—
1.9e+00
3.4e-01
cases:3.61%
controls:4.55%
cases:14.46%
controls:1.88%
cases:19.28%
controls:0.73%
—
—
—
—
cases:10.63%
controls:1.76%
cases:9.16%
controls:6.67%
6
75
160
1575
24
31
142
1619
32
12
134
1638
—
—
17
29
143
1616
12
102
119
1427
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
7.8e-02
3.0e-01
2.4e+00
—
2.7e+00
1.5e+00
7.7e-01
cases:22.29%
controls:20.97%
cases:22.29%
controls:17.52%
cases:31.93%
controls:4.00%
—
—
cases:38.79%
controls:4.00%
cases:50.00%
controls:18.72%
cases:58.78%
controls:39.70%
37
346
129
1304
37
289
129
1361
53
66
113
1584
—
64
66
101
1583
80
308
80
1337
77
607
54
922
Treatment plan or consultation
WZC00 [2001310885]
—
—
—
—
3.1e+00
3.0e+00
1.2e+00
—
—
—
—
—
—
—
—
cases:8.48%
controls:0.42%
cases:28.13%
controls:2.01%
cases:20.61%
controls:7.26%
—
—
—
—
14
7
151
1642
45
33
115
1612
27
111
104
1418
Inpatient Visit
IP [9201]
-6.4e-02
7.4e-01
4.0e+00
1.0e+50
—
2.3e+00
9.0e-01
cases:4.22%
controls:4.48%
cases:4.22%
controls:2.06%
cases:14.46%
controls:0.30%
cases:15.66%
controls:0.00%
—
—
cases:18.13%
controls:2.25%
cases:17.56%
controls:7.98%
7
74
159
1576
7
34
159
1616
24
5
142
1645
26
0
140
1650
—
29
37
131
1608
23
122
108
1407
INR in Blood by Coagulation assay
34714-6 [3032080]
-8.2e-01
7.1e-01
3.4e+00
1.0e+50
2.5e+00
1.2e+00
3.2e-01
cases:3.61%
controls:7.88%
cases:9.64%
controls:4.97%
cases:24.10%
controls:1.09%
cases:4.82%
controls:0.00%
cases:11.52%
controls:1.03%
cases:12.50%
controls:4.26%
cases:14.50%
controls:10.92%
6
130
160
1520
16
82
150
1568
40
18
126
1632
8
0
158
1650
19
17
146
1632
20
70
140
1575
19
167
112
1362
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
—
—
—
—
2.2e+00
2.4e+00
2.5e+00
—
—
—
—
—
—
—
—
cases:3.64%
controls:0.42%
cases:10.00%
controls:1.03%
cases:12.98%
controls:1.24%
—
—
—
—
6
7
159
1642
16
17
144
1628
17
19
114
1510
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
-1.6e-01
-2.4e-01
1.2e+00
—
3.2e+00
2.6e+00
1.2e+00
cases:7.83%
controls:9.09%
cases:4.82%
controls:6.06%
cases:4.22%
controls:1.27%
—
—
cases:20.00%
controls:1.03%
cases:48.13%
controls:6.20%
cases:35.88%
controls:14.72%
13
150
153
1500
8
100
158
1550
7
21
159
1629
—
33
17
132
1632
77
102
83
1543
47
225
84
1304
carbamazepine; oral, rectal
N03AF01 [21604417]
-1.0e+50
—
—
—
1.0e+50
3.3e+00
3.5e+00
cases:0.00%
controls:0.42%
—
—
—
—
—
—
cases:3.03%
controls:0.00%
cases:9.38%
controls:0.36%
cases:13.74%
controls:0.46%
0
7
166
1643
—
—
—
5
0
160
1649
15
6
145
1639
18
7
113
1522
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
-2.9e-01
4.4e-01
3.9e+00
1.0e+50
—
2.1e+00
9.4e-01
cases:4.22%
controls:5.58%
cases:3.61%
controls:2.36%
cases:12.65%
controls:0.30%
cases:14.46%
controls:0.00%
—
—
cases:13.13%
controls:1.88%
cases:16.03%
controls:6.93%
7
92
159
1558
6
39
160
1611
21
5
145
1645
24
0
142
1650
—
21
31
139
1614
21
106
110
1423
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
-1.0e+50
—
—
—
—
4.2e+00
2.6e+00
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
cases:20.00%
controls:0.36%
cases:9.92%
controls:0.78%
0
9
166
1641
—
—
—
—
32
6
128
1639
13
12
118
1517
Emergency Room and Inpatient Visit
ERIP [262]
—
1.2e+00
4.1e+00
1.0e+50
—
1.5e+00
4.8e-01
—
—
cases:7.83%
controls:2.61%
cases:15.06%
controls:0.30%
cases:4.82%
controls:0.00%
—
—
cases:10.00%
controls:2.43%
cases:16.03%
controls:10.53%
—
13
43
153
1607
25
5
141
1645
8
0
158
1650
—
16
40
144
1605
21
161
110
1368
Case Management Agency
251B00000X [38004193]
-1.7e-01
-6.2e-02
1.3e+00
2.3e+00
1.8e+00
1.3e+00
2.4e-01
cases:63.25%
controls:67.21%
cases:57.83%
controls:59.33%
cases:54.22%
controls:24.48%
cases:10.84%
controls:1.15%
cases:63.64%
controls:22.56%
cases:85.00%
controls:61.22%
cases:83.97%
controls:80.44%
105
1109
61
541
96
979
70
671
90
404
76
1246
18
19
148
1631
105
372
60
1277
136
1007
24
638
110
1230
21
299
Emergency Medicine
93 [38004510]
-5.5e-02
5.0e-01
3.0e+00
1.0e+50
2.3e+00
1.2e+00
2.8e-01
cases:12.65%
controls:13.27%
cases:12.05%
controls:7.70%
cases:19.28%
controls:1.15%
cases:6.02%
controls:0.00%
cases:10.30%
controls:1.09%
cases:22.50%
controls:8.15%
cases:28.24%
controls:22.96%
21
219
145
1431
20
127
146
1523
32
19
134
1631
10
0
156
1650
17
18
148
1631
36
134
124
1511
37
351
94
1178
Supplier / Service Provider
OMOP5117446 [33004]
-2.0e+00
—
1.8e+00
—
—
4.2e+00
2.3e+00
cases:5.42%
controls:30.30%
—
—
cases:7.23%
controls:1.21%
—
—
—
—
cases:22.50%
controls:0.43%
cases:9.16%
controls:0.98%
9
500
157
1150
—
12
20
154
1630
—
—
36
7
124
1638
12
15
119
1514
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
-2.5e-01
4.3e-01
2.0e+00
—
2.7e+00
1.6e+00
4.9e-01
cases:6.02%
controls:7.64%
cases:6.63%
controls:4.42%
cases:7.23%
controls:1.09%
—
—
cases:8.48%
controls:0.61%
cases:18.13%
controls:4.19%
cases:17.56%
controls:11.58%
10
126
156
1524
11
73
155
1577
12
18
154
1632
—
14
10
151
1639
29
69
131
1576
23
177
108
1352
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
—
1.0e+00
—
—
—
4.2e+00
2.0e+00
—
—
cases:3.61%
controls:1.33%
—
—
—
—
—
—
cases:47.50%
controls:1.28%
cases:24.43%
controls:4.32%
—
6
22
160
1628
—
—
—
76
21
84
1624
32
66
99
1463
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
-4.9e-01
9.6e-02
2.3e+00
—
2.6e+00
1.1e+00
1.5e-01
cases:18.07%
controls:26.48%
cases:22.29%
controls:20.67%
cases:31.93%
controls:4.61%
—
—
cases:40.61%
controls:4.61%
cases:45.63%
controls:21.09%
cases:45.80%
controls:42.12%
30
437
136
1213
37
341
129
1309
53
76
113
1574
—
67
76
98
1573
73
347
87
1298
60
644
71
885
zopiclone; oral
N05CF01 [21604654]
-3.8e-01
-1.6e-01
2.1e+00
—
2.4e+00
1.5e+00
7.7e-01
cases:4.22%
controls:6.06%
cases:3.01%
controls:3.52%
cases:4.82%
controls:0.61%
—
—
cases:7.88%
controls:0.79%
cases:11.25%
controls:2.86%
cases:9.92%
controls:4.84%
7
100
159
1550
5
58
161
1592
8
10
158
1640
—
13
13
152
1636
18
47
142
1598
13
74
118
1455
Office Visit
OMOP4822458 [581477]
-7.1e-01
3.6e-01
—
—
2.5e+00
2.2e+00
1.2e+00
cases:4.82%
controls:9.33%
cases:3.61%
controls:2.55%
—
—
—
—
cases:7.27%
controls:0.67%
cases:16.25%
controls:2.19%
cases:12.98%
controls:4.12%
8
154
158
1496
6
42
160
1608
—
—
12
11
153
1638
26
36
134
1609
17
63
114
1466
12 lead EKG panel
34534-8 [3044889]
-3.1e-01
3.5e-01
3.6e+00
—
2.2e+00
-1.5e-01
1.9e-02
cases:12.05%
controls:15.70%
cases:9.64%
controls:6.97%
cases:21.08%
controls:0.73%
—
—
cases:7.27%
controls:0.85%
cases:6.88%
controls:7.90%
cases:22.90%
controls:22.56%
20
259
146
1391
16
115
150
1535
35
12
131
1638
—
12
14
153
1635
11
130
149
1515
30
345
101
1184
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
-1.8e-01
2.3e-01
1.5e+00
—
3.1e+00
9.5e-01
3.7e-01
cases:25.30%
controls:28.85%
cases:18.07%
controls:14.91%
cases:8.43%
controls:2.00%
—
—
cases:27.88%
controls:1.64%
cases:32.50%
controls:15.74%
cases:44.27%
controls:35.45%
42
476
124
1174
30
246
136
1404
14
33
152
1617
—
46
27
119
1622
52
259
108
1386
58
542
73
987
Normoblasts [#/volume] in Blood
715-3 [3021589]
-1.1e+00
-1.2e-01
1.6e+00
—
2.2e+00
1.8e+00
5.3e-01
cases:3.01%
controls:8.18%
cases:6.63%
controls:7.39%
cases:7.23%
controls:1.52%
—
—
cases:12.12%
controls:1.58%
cases:31.88%
controls:7.17%
cases:26.72%
controls:17.72%
5
135
161
1515
11
122
155
1528
12
25
154
1625
—
20
26
145
1623
51
118
109
1527
35
271
96
1258
Psychologist
Z2445 [2001311558]
-1.0e+50
-1.0e+50
—
—
—
2.5e+00
3.0e+00
cases:0.00%
controls:1.09%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
cases:3.75%
controls:0.30%
cases:6.11%
controls:0.33%
0
18
166
1632
0
5
166
1645
—
—
—
6
5
154
1640
8
5
123
1524
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
—
2.8e+00
1.0e+50
1.0e+50
1.0e+50
—
2.6e+00
—
—
cases:4.82%
controls:0.30%
cases:9.64%
controls:0.00%
cases:3.61%
controls:0.00%
cases:3.03%
controls:0.00%
—
—
cases:12.21%
controls:1.05%
—
8
5
158
1645
16
0
150
1650
6
0
160
1650
5
0
160
1649
—
16
16
115
1513
Infiltration anesthesia
WX110 [2001310767]
-2.8e-01
4.6e-02
1.9e+00
1.0e+50
2.6e+00
7.9e-01
2.9e-01
cases:19.28%
controls:23.94%
cases:9.04%
controls:8.67%
cases:8.43%
controls:1.33%
cases:18.07%
controls:0.00%
cases:12.12%
controls:1.03%
cases:16.88%
controls:8.45%
cases:29.01%
controls:23.41%
32
395
134
1255
15
143
151
1507
14
22
152
1628
30
0
136
1650
20
17
145
1632
27
139
133
1506
38
358
93
1171
Differential panel, method unspecified - Blood
69738-3 [42870588]
-6.6e-01
-3.6e-01
1.2e+00
—
2.2e+00
2.2e+00
8.8e-01
cases:3.61%
controls:6.79%
cases:3.61%
controls:5.09%
cases:3.01%
controls:0.97%
—
—
cases:7.27%
controls:0.85%
cases:30.63%
controls:4.68%
cases:20.61%
controls:9.74%
6
112
160
1538
6
84
160
1566
5
16
161
1634
—
12
14
153
1635
49
77
111
1568
27
149
104
1380
Immunohistochemistry procedure
117617002 [4035726]
-1.0e+50
—
—
1.0e+50
1.0e+50
3.0e+00
2.3e+00
cases:0.00%
controls:1.21%
—
—
—
—
cases:28.31%
controls:0.00%
cases:9.09%
controls:0.00%
cases:8.75%
controls:0.49%
cases:10.69%
controls:1.18%
0
20
166
1630
—
—
47
0
119
1650
15
0
150
1649
14
8
146
1637
14
18
117
1511
Pharmacy visit
OMOP4822462 [581458]
-2.0e-01
1.3e-01
1.2e+00
1.2e+00
2.3e+00
1.7e+00
2.2e+00
cases:86.75%
controls:88.91%
cases:78.31%
controls:75.94%
cases:64.46%
controls:36.00%
cases:5.42%
controls:1.70%
cases:84.24%
controls:34.75%
cases:95.00%
controls:77.14%
cases:99.24%
controls:93.26%
144
1467
22
183
130
1253
36
397
107
594
59
1056
9
28
157
1622
139
573
26
1076
152
1269
8
376
130
1426
1
103
General anesthesia, balanced
WX408 [2001310808]
—
—
1.0e+50
1.0e+50
1.0e+50
2.8e+00
2.3e+00
—
—
—
—
cases:3.01%
controls:0.00%
cases:7.23%
controls:0.00%
cases:3.64%
controls:0.00%
cases:5.63%
controls:0.36%
cases:10.69%
controls:1.18%
—
—
5
0
161
1650
12
0
154
1650
6
0
159
1649
9
6
151
1639
14
18
117
1511
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
-3.4e-01
-4.2e-02
1.0e+00
—
2.3e+00
1.9e+00
8.0e-01
cases:13.86%
controls:18.48%
cases:11.45%
controls:11.88%
cases:7.23%
controls:2.73%
—
—
cases:18.79%
controls:2.24%
cases:48.13%
controls:12.16%
cases:45.04%
controls:26.88%
23
305
143
1345
19
196
147
1454
12
45
154
1605
—
31
37
134
1612
77
200
83
1445
59
411
72
1118
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
-3.2e-01
-3.4e-01
3.0e-01
—
1.8e+00
2.2e+00
9.3e-01
cases:9.64%
controls:12.85%
cases:6.63%
controls:9.09%
cases:4.22%
controls:3.15%
—
—
cases:15.76%
controls:2.97%
cases:47.50%
controls:9.18%
cases:38.93%
controls:20.08%
16
212
150
1438
11
150
155
1500
7
52
159
1598
—
26
49
139
1600
76
151
84
1494
51
307
80
1222
Cystostatic therapy of methastized malignancy
WD105 [2001310678]
-1.0e+50
-1.0e+50
—
—
—
2.5e+00
2.3e+00
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.42%
—
—
—
—
—
—
cases:3.75%
controls:0.30%
cases:3.82%
controls:0.39%
0
6
166
1644
0
7
166
1643
—
—
—
6
5
154
1640
5
6
126
1523
EKG study
11524-6 [3013512]
4.2e-02
7.8e-01
3.6e+00
—
—
1.2e+00
2.0e-01
cases:5.42%
controls:5.21%
cases:6.63%
controls:3.15%
cases:11.45%
controls:0.36%
—
—
—
—
cases:9.38%
controls:2.92%
cases:8.40%
controls:7.00%
9
86
157
1564
11
52
155
1598
19
6
147
1644
—
—
15
48
145
1597
11
107
120
1422
methylprednisolone; oral, parenteral
H02AB04 [21602732]
—
—
—
—
—
2.8e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:6.88%
controls:0.43%
cases:6.11%
controls:0.92%
—
—
—
—
—
11
7
149
1638
8
14
123
1515
Monocytes [#/volume] in Blood
26484-6 [3001604]
-3.7e-01
-3.2e-01
9.3e-01
—
1.9e+00
2.2e+00
7.2e-01
cases:7.83%
controls:10.97%
cases:5.42%
controls:7.33%
cases:3.61%
controls:1.45%
—
—
cases:9.09%
controls:1.52%
cases:39.38%
controls:6.75%
cases:30.53%
controls:17.59%
13
181
153
1469
9
121
157
1529
6
24
160
1626
—
15
25
150
1624
63
111
97
1534
40
269
91
1260
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
-3.6e-01
-3.0e-01
9.7e-01
—
1.8e+00
2.1e+00
8.6e-01
cases:7.83%
controls:10.85%
cases:5.42%
controls:7.21%
cases:3.61%
controls:1.39%
—
—
cases:8.48%
controls:1.52%
cases:35.63%
controls:6.26%
cases:30.53%
controls:15.63%
13
179
153
1471
9
119
157
1531
6
23
160
1627
—
14
25
151
1624
57
103
103
1542
40
239
91
1290
Monocytes/Leukocytes in Blood
26485-3 [3019069]
-3.5e-01
-3.1e-01
1.0e+00
—
1.8e+00
2.1e+00
8.6e-01
cases:7.83%
controls:10.79%
cases:5.42%
controls:7.27%
cases:3.61%
controls:1.33%
—
—
cases:8.48%
controls:1.52%
cases:35.63%
controls:6.32%
cases:30.53%
controls:15.70%
13
178
153
1472
9
120
157
1530
6
22
160
1628
—
14
25
151
1624
57
104
103
1541
40
240
91
1289
Basophils [#/volume] in Blood
26444-0 [3006315]
-4.0e-01
-3.3e-01
8.9e-01
—
1.9e+00
2.2e+00
7.1e-01
cases:7.83%
controls:11.21%
cases:5.42%
controls:7.39%
cases:3.61%
controls:1.52%
—
—
cases:9.09%
controls:1.52%
cases:39.38%
controls:6.87%
cases:30.53%
controls:17.79%
13
185
153
1465
9
122
157
1528
6
25
160
1625
—
15
25
150
1624
63
113
97
1532
40
272
91
1257
Basophils/Leukocytes in Blood
30180-4 [3022096]
-3.5e-01
-3.0e-01
9.7e-01
—
1.8e+00
2.1e+00
8.7e-01
cases:7.83%
controls:10.79%
cases:5.42%
controls:7.21%
cases:3.61%
controls:1.39%
—
—
cases:8.48%
controls:1.52%
cases:35.00%
controls:6.26%
cases:30.53%
controls:15.57%
13
178
153
1472
9
119
157
1531
6
23
160
1627
—
14
25
151
1624
56
103
104
1542
40
238
91
1291
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
-3.8e-01
-1.7e-01
7.4e-01
—
1.8e+00
2.0e+00
8.6e-01
cases:7.83%
controls:11.03%
cases:6.02%
controls:7.09%
cases:3.01%
controls:1.45%
—
—
cases:8.48%
controls:1.46%
cases:35.63%
controls:6.69%
cases:30.53%
controls:15.70%
13
182
153
1468
10
117
156
1533
5
24
161
1626
—
14
24
151
1625
57
110
103
1535
40
240
91
1289
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
—
—
—
—
—
2.9e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:0.43%
cases:9.16%
controls:1.70%
—
—
—
—
—
12
7
148
1638
12
26
119
1503
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
—
—
—
—
—
2.8e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:0.49%
cases:12.21%
controls:2.09%
—
—
—
—
—
12
8
148
1637
16
32
115
1497
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
—
1.8e+00
—
1.0e+50
—
2.8e+00
7.4e-01
—
—
cases:7.23%
controls:1.21%
—
—
cases:3.61%
controls:0.00%
—
—
cases:10.00%
controls:0.67%
cases:6.11%
controls:3.01%
—
12
20
154
1630
—
6
0
160
1650
—
16
11
144
1634
8
46
123
1483
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
-3.9e-01
-2.4e-01
9.7e-01
—
1.8e+00
2.0e+00
8.3e-01
cases:7.83%
controls:11.15%
cases:6.02%
controls:7.52%
cases:3.61%
controls:1.39%
—
—
cases:8.48%
controls:1.52%
cases:35.63%
controls:6.87%
cases:30.53%
controls:16.02%
13
184
153
1466
10
124
156
1526
6
23
160
1627
—
14
25
151
1624
57
113
103
1532
40
245
91
1284
Eosinophils [#/volume] in Blood
26449-9 [3013115]
-4.0e-01
-3.9e-01
7.8e-01
—
1.8e+00
2.1e+00
7.0e-01
cases:8.43%
controls:12.12%
cases:5.42%
controls:7.82%
cases:3.61%
controls:1.70%
—
—
cases:9.70%
controls:1.76%
cases:39.38%
controls:7.36%
cases:31.30%
controls:18.44%
14
200
152
1450
9
129
157
1521
6
28
160
1622
—
16
29
149
1620
63
121
97
1524
41
282
90
1247
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
-1.5e-01
3.7e-01
2.2e+00
—
2.4e+00
-3.4e-02
4.5e-02
cases:15.66%
controls:17.76%
cases:12.65%
controls:9.09%
cases:9.04%
controls:1.09%
—
—
cases:7.88%
controls:0.79%
cases:9.38%
controls:9.67%
cases:29.77%
controls:28.84%
26
293
140
1357
21
150
145
1500
15
18
151
1632
—
13
13
152
1636
15
159
145
1486
39
441
92
1088
Respiratory and circulatory monitoring
WX700 [2001310817]
—
—
—
1.0e+50
—
2.6e+00
2.0e+00
—
—
—
—
—
—
cases:10.84%
controls:0.00%
—
—
cases:11.25%
controls:0.97%
cases:12.98%
controls:1.96%
—
—
—
18
0
148
1650
—
18
16
142
1629
17
30
114
1499
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
-1.0e+50
—
—
1.0e+50
1.0e+50
2.6e+00
1.9e+00
cases:0.00%
controls:0.61%
—
—
—
—
cases:15.06%
controls:0.00%
cases:11.52%
controls:0.00%
cases:6.25%
controls:0.49%
cases:10.69%
controls:1.77%
0
10
166
1640
—
—
25
0
141
1650
19
0
146
1649
10
8
150
1637
14
27
117
1502
oxazepam; oral
N05BA04 [21604569]
—
4.7e-01
1.7e+00
—
2.3e+00
1.3e+00
9.7e-01
—
—
cases:4.22%
controls:2.67%
cases:3.61%
controls:0.67%
—
—
cases:6.67%
controls:0.73%
cases:9.38%
controls:2.86%
cases:13.74%
controls:5.69%
—
7
44
159
1606
6
11
160
1639
—
11
12
154
1637
15
47
145
1598
18
87
113
1442
pH of Serum or Plasma
2753-2 [3018418]
—
7.4e-01
2.9e+00
—
2.3e+00
1.6e+00
3.7e-01
—
—
cases:7.23%
controls:3.58%
cases:10.24%
controls:0.61%
—
—
cases:3.03%
controls:0.30%
cases:12.50%
controls:2.92%
cases:11.45%
controls:8.18%
—
12
59
154
1591
17
10
149
1640
—
5
5
160
1644
20
48
140
1597
15
125
116
1404
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
-1.0e+50
—
—
—
—
2.1e+00
2.3e+00
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
cases:3.75%
controls:0.49%
cases:9.16%
controls:0.98%
0
12
166
1638
—
—
—
—
6
8
154
1637
12
15
119
1514
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
-1.0e+50
—
—
1.0e+50
1.0e+50
2.7e+00
1.6e+00
cases:0.00%
controls:0.36%
—
—
—
—
cases:13.25%
controls:0.00%
cases:11.52%
controls:0.00%
cases:6.25%
controls:0.43%
cases:7.63%
controls:1.57%
0
6
166
1644
—
—
22
0
144
1650
19
0
146
1649
10
7
150
1638
10
24
121
1505
Short blood count panel - Blood
55429-5 [40758558]
-3.3e-01
—
—
—
2.4e+00
2.0e+00
6.9e-01
cases:4.22%
controls:5.76%
—
—
—
—
—
—
cases:8.48%
controls:0.85%
cases:18.13%
controls:2.98%
cases:12.98%
controls:6.93%
7
95
159
1555
—
—
—
14
14
151
1635
29
49
131
1596
17
106
114
1423
lamotrigine; oral
N03AX09 [21604431]
—
—
—
—
—
2.1e+00
2.2e+00
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:0.55%
cases:7.63%
controls:0.92%
—
—
—
—
—
7
9
153
1636
10
14
121
1515
Laceration/cut
S18 [2002000983]
1.8e-01
—
—
—
4.2e+00
8.7e-01
4.1e-01
cases:7.83%
controls:6.61%
—
—
—
—
—
—
cases:17.58%
controls:0.30%
cases:5.63%
controls:2.43%
cases:11.45%
controls:7.91%
13
109
153
1541
—
—
—
29
5
136
1644
9
40
151
1605
15
121
116
1408
pH of Arterial blood
2744-1 [3019977]
—
—
—
1.0e+50
—
2.6e+00
1.6e+00
—
—
—
—
—
—
cases:22.89%
controls:0.00%
—
—
cases:10.00%
controls:0.79%
cases:13.74%
controls:3.20%
—
—
—
38
0
128
1650
—
16
13
144
1632
18
49
113
1480
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
—
—
—
1.0e+50
—
2.6e+00
1.6e+00
—
—
—
—
—
—
cases:22.89%
controls:0.00%
—
—
cases:9.38%
controls:0.79%
cases:13.74%
controls:3.14%
—
—
—
38
0
128
1650
—
15
13
145
1632
18
48
113
1481
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
—
—
—
1.0e+50
—
2.6e+00
1.6e+00
—
—
—
—
—
—
cases:22.89%
controls:0.00%
—
—
cases:9.38%
controls:0.79%
cases:13.74%
controls:3.14%
—
—
—
38
0
128
1650
—
15
13
145
1632
18
48
113
1481
Base excess in Arterial blood by calculation
1925-7 [3003396]
—
—
—
1.0e+50
—
2.6e+00
1.5e+00
—
—
—
—
—
—
cases:22.89%
controls:0.00%
—
—
cases:10.00%
controls:0.79%
cases:12.21%
controls:3.14%
—
—
—
38
0
128
1650
—
16
13
144
1632
16
48
115
1481
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
—
9.3e-01
—
—
—
2.4e+00
1.7e+00
—
—
cases:3.01%
controls:1.21%
—
—
—
—
—
—
cases:9.38%
controls:0.97%
cases:12.21%
controls:2.49%
—
5
20
161
1630
—
—
—
15
16
145
1629
16
38
115
1491
Very extensive MRI examination of brain with high intensity magnet
AA1DG [2001300120]
—
—
1.0e+50
1.0e+50
—
—
4.0e+00
—
—
—
—
cases:9.64%
controls:0.00%
cases:3.61%
controls:0.00%
—
—
—
—
cases:15.27%
controls:0.33%
—
—
16
0
150
1650
6
0
160
1650
—
—
20
5
111
1524
lacosamide; oral, parenteral
N03AX18 [21604440]
—
—
1.0e+50
—
—
—
3.9e+00
—
—
—
—
cases:3.01%
controls:0.00%
—
—
—
—
—
—
cases:14.50%
controls:0.33%
—
—
5
0
161
1650
—
—
—
19
5
112
1524
oxycodone; oral, parenteral
N02AA05 [21604260]
—
—
-1.0e+50
—
—
1.9e+00
2.0e+00
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
cases:4.38%
controls:0.67%
cases:9.92%
controls:1.44%
—
—
0
6
166
1644
—
—
7
11
153
1634
13
22
118
1507
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
-4.8e-01
-2.5e-01
8.1e-01
—
1.8e+00
2.1e+00
6.7e-01
cases:7.83%
controls:12.06%
cases:6.02%
controls:7.64%
cases:3.61%
controls:1.64%
—
—
cases:9.09%
controls:1.58%
cases:39.38%
controls:7.42%
cases:29.77%
controls:17.85%
13
199
153
1451
10
126
156
1524
6
27
160
1623
—
15
26
150
1623
63
122
97
1523
39
273
92
1256
Neuropsychological investigation
XA800 [2001300412]
—
—
—
—
—
—
3.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:16.03%
controls:0.39%
—
—
—
—
—
—
21
6
110
1523
Bacteria identified in Blood by Culture
600-7 [3023368]
—
—
—
—
2.2e+00
1.6e+00
1.6e-01
—
—
—
—
—
—
—
—
cases:3.64%
controls:0.42%
cases:8.75%
controls:1.82%
cases:7.63%
controls:6.61%
—
—
—
—
6
7
159
1642
14
30
146
1615
10
101
121
1428
Epilepsy
G40 [45595935]
-1.0e+50
1.0e+50
1.0e+50
—
1.0e+50
—
3.7e+00
cases:0.00%
controls:0.48%
cases:5.42%
controls:0.00%
cases:7.23%
controls:0.00%
—
—
cases:7.88%
controls:0.00%
—
—
cases:12.21%
controls:0.33%
0
8
166
1642
9
0
157
1650
12
0
154
1650
—
13
0
152
1649
—
16
5
115
1524
Scheduled procedure
ZXD10 [2001311387]
—
—
—
1.0e+50
1.0e+50
2.1e+00
1.5e+00
—
—
—
—
—
—
cases:6.63%
controls:0.00%
cases:5.45%
controls:0.00%
cases:6.88%
controls:0.85%
cases:7.63%
controls:1.83%
—
—
—
11
0
155
1650
9
0
156
1649
11
14
149
1631
10
28
121
1501
Epilepsy, unspecified
G40.9 [45562083]
—
—
1.0e+50
—
—
—
3.6e+00
—
—
—
—
cases:4.22%
controls:0.00%
—
—
—
—
—
—
cases:16.03%
controls:0.52%
—
—
7
0
159
1650
—
—
—
21
8
110
1521
Malignant tumour
130 [2001600128]
-1.0e+50
—
—
—
1.0e+50
—
3.6e+00
cases:0.00%
controls:0.73%
—
—
—
—
—
—
cases:11.52%
controls:0.00%
—
—
cases:12.21%
controls:0.39%
0
12
166
1638
—
—
—
19
0
146
1649
—
16
6
115
1523
Teaching
WZC30 [2001310891]
—
—
—
—
—
3.5e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:14.38%
controls:0.49%
cases:8.40%
controls:2.62%
—
—
—
—
—
23
8
137
1637
11
40
120
1489
ABO and Rh group [Type] in Blood
882-1 [3003694]
-2.6e-01
5.0e-01
—
—
3.5e+00
9.0e-01
-1.3e-01
cases:4.22%
controls:5.39%
cases:4.82%
controls:2.97%
—
—
—
—
cases:9.09%
controls:0.30%
cases:4.38%
controls:1.82%
cases:6.87%
controls:7.78%
7
89
159
1561
8
49
158
1601
—
—
15
5
150
1644
7
30
153
1615
9
119
122
1410
Physical Medicine And Rehabilitation
25 [38004468]
-3.5e-01
—
—
—
—
2.3e+00
1.0e+00
cases:4.22%
controls:5.88%
—
—
—
—
—
—
—
—
cases:13.75%
controls:1.58%
cases:15.27%
controls:5.95%
7
97
159
1553
—
—
—
—
22
26
138
1619
20
91
111
1438
hydrocortisone; oral, parenteral
H02AB09 [21602737]
—
—
—
—
—
3.3e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:0.36%
cases:4.58%
controls:1.18%
—
—
—
—
—
14
6
146
1639
6
18
125
1511
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
-3.6e-01
5.9e-01
—
—
3.2e+00
8.3e-01
3.6e-02
cases:6.02%
controls:8.42%
cases:7.23%
controls:4.12%
—
—
—
—
cases:7.27%
controls:0.30%
cases:8.75%
controls:4.01%
cases:12.21%
controls:11.84%
10
139
156
1511
12
68
154
1582
—
—
12
5
153
1644
14
66
146
1579
16
181
115
1348
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
-1.0e+50
—
—
—
—
3.2e+00
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
cases:6.88%
controls:0.30%
—
—
0
10
166
1640
—
—
—
—
11
5
149
1640
—
Epilepsy and comparable convulsive disorders
111 [2001600111]
—
—
1.0e+50
—
—
—
3.1e+00
—
—
—
—
cases:20.48%
controls:0.00%
—
—
—
—
—
—
cases:6.87%
controls:0.33%
—
—
34
0
132
1650
—
—
—
9
5
122
1524
macrogol; oral
A06AD15 [21600575]
—
-1.0e+50
—
—
—
3.0e+00
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
cases:6.88%
controls:0.36%
—
—
—
0
7
166
1643
—
—
—
11
6
149
1639
—
Radical radiotherapy
WF002 [2001310701]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.40%
controls:0.52%
—
—
—
—
—
—
11
8
120
1521
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
-3.8e-02
5.7e-01
—
—
—
2.7e+00
6.9e-01
cases:6.02%
controls:6.24%
cases:4.82%
controls:2.79%
—
—
—
—
—
—
cases:26.88%
controls:2.37%
cases:14.50%
controls:7.85%
10
103
156
1547
8
46
158
1604
—
—
—
43
39
117
1606
19
120
112
1409
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
—
—
—
1.0e+50
—
2.5e+00
1.0e+00
—
—
—
—
—
—
cases:7.83%
controls:0.00%
—
—
cases:3.75%
controls:0.30%
cases:3.82%
controls:1.44%
—
—
—
13
0
153
1650
—
6
5
154
1640
5
22
126
1507
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
-1.0e+50
-1.0e+50
—
—
—
—
2.4e+00
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
cases:6.87%
controls:0.65%
0
10
166
1640
0
5
166
1645
—
—
—
—
9
10
122
1519
Tissue Pathology biopsy report
66121-5 [40768804]
1.8e-01
-6.6e-02
—
1.0e+50
—
1.3e+00
1.1e+00
cases:9.04%
controls:7.70%
cases:3.01%
controls:3.21%
—
—
cases:30.12%
controls:0.00%
—
—
cases:10.63%
controls:3.22%
cases:21.37%
controls:8.04%
15
127
151
1523
5
53
161
1597
—
50
0
116
1650
—
17
53
143
1592
28
123
103
1406
Headache
R51.80 [2000503603]
-1.0e+50
—
—
—
—
2.4e+00
1.0e+00
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
cases:5.00%
controls:0.49%
cases:6.11%
controls:2.29%
0
29
166
1621
—
—
—
—
8
8
152
1637
8
35
123
1494
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
—
—
—
—
1.0e+50
2.4e+00
—
—
—
—
—
—
—
—
—
cases:3.03%
controls:0.00%
cases:3.75%
controls:0.36%
—
—
—
—
—
—
5
0
160
1649
6
6
154
1639
—
Right side
ZXA00 [2001311346]
—
-1.0e+50
—
1.0e+50
—
2.4e+00
1.2e+00
—
—
cases:0.00%
controls:0.91%
—
—
cases:4.22%
controls:0.00%
—
—
cases:3.13%
controls:0.30%
cases:4.58%
controls:1.37%
—
0
15
166
1635
—
7
0
159
1650
—
5
5
155
1640
6
21
125
1508
ECG with 12 standard connections
XF400 [2001303368]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.13%
controls:0.30%
—
—
—
—
—
—
—
5
5
155
1640
—
Pulmonary embolism without mention of acute cor pulmonale
I26.9 [45552785]
-1.0e+50
—
—
—
—
2.4e+00
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
cases:3.13%
controls:0.30%
—
—
0
8
166
1642
—
—
—
—
5
5
155
1640
—
amoxicillin; oral, parenteral
J01CA04 [21602823]
-5.4e-01
-4.5e-02
2.3e+00
—
—
1.8e-02
-1.7e-02
cases:14.46%
controls:22.55%
cases:6.63%
controls:6.91%
cases:4.82%
controls:0.48%
—
—
—
—
cases:5.63%
controls:5.53%
cases:18.32%
controls:18.57%
24
372
142
1278
11
114
155
1536
8
8
158
1642
—
—
9
91
151
1554
24
284
107
1245
temazepam; oral
N05CD07 [21604642]
-1.0e+50
—
—
—
2.3e+00
1.5e+00
1.0e+00
cases:0.00%
controls:2.48%
—
—
—
—
—
—
cases:3.64%
controls:0.36%
cases:5.00%
controls:1.16%
cases:6.11%
controls:2.29%
0
41
166
1609
—
—
—
6
6
159
1643
8
19
152
1626
8
35
123
1494
Psychiatry
26 [38004469]
-3.5e-01
3.9e-01
6.1e-01
—
9.1e-01
1.4e+00
8.9e-01
cases:6.63%
controls:9.15%
cases:7.83%
controls:5.45%
cases:4.82%
controls:2.67%
—
—
cases:6.67%
controls:2.79%
cases:18.75%
controls:5.47%
cases:21.37%
controls:10.01%
11
151
155
1499
13
90
153
1560
8
44
158
1606
—
11
46
154
1603
30
90
130
1555
28
153
103
1376
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
-1.0e+50
—
—
1.0e+50
—
2.2e+00
1.1e+00
cases:0.00%
controls:0.55%
—
—
—
—
cases:12.65%
controls:0.00%
—
—
cases:4.38%
controls:0.49%
cases:7.63%
controls:2.75%
0
9
166
1641
—
—
21
0
145
1650
—
7
8
153
1637
10
42
121
1487
More than three and less than five hours
ZXE20 [2001311408]
-1.0e+50
—
—
1.0e+50
1.0e+50
—
2.2e+00
cases:0.00%
controls:2.00%
—
—
—
—
cases:6.02%
controls:0.00%
cases:4.24%
controls:0.00%
—
—
cases:4.58%
controls:0.52%
0
33
166
1617
—
—
10
0
156
1650
7
0
158
1649
—
6
8
125
1521
Bacteria [Presence] in Urine
87829-8 [36304419]
-4.4e-01
—
—
—
2.2e+00
8.0e-01
4.1e-01
cases:3.01%
controls:4.61%
—
—
—
—
—
—
cases:3.64%
controls:0.42%
cases:5.00%
controls:2.31%
cases:9.92%
controls:6.80%
5
76
161
1574
—
—
—
6
7
159
1642
8
38
152
1607
13
104
118
1425
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:7.50%
controls:0.91%
—
—
—
—
—
—
—
12
15
148
1630
—
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
3.6e-02
—
—
—
—
2.1e+00
4.9e-01
cases:3.01%
controls:2.91%
—
—
—
—
—
—
—
—
cases:10.00%
controls:1.28%
cases:6.87%
controls:4.32%
5
48
161
1602
—
—
—
—
16
21
144
1624
9
66
122
1463
Oxygen saturation in Arterial blood
2708-6 [3016502]
—
—
—
1.0e+50
—
2.1e+00
1.1e+00
—
—
—
—
—
—
cases:12.65%
controls:0.00%
—
—
cases:4.38%
controls:0.55%
cases:7.63%
controls:2.68%
—
—
—
21
0
145
1650
—
7
9
153
1636
10
41
121
1488
Speech therapy
R4130 [2001310235]
—
—
—
—
—
1.0e+50
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:5.63%
controls:0.00%
cases:4.58%
controls:0.59%
—
—
—
—
—
9
0
151
1645
6
9
125
1520
potassium chloride; oral
A12BA01 [21600877]
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.75%
controls:0.49%
—
—
—
—
—
—
—
6
8
154
1637
—
lactulose; oral
A06AD11 [21600571]
-1.0e+50
-1.0e+50
—
—
—
2.1e+00
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:3.75%
controls:0.49%
—
—
0
16
166
1634
0
13
166
1637
—
—
—
6
8
154
1637
—
Cathetrisation of artery
TPH07 [2001309747]
-1.0e+50
—
—
1.0e+50
—
—
2.1e+00
cases:0.00%
controls:0.79%
—
—
—
—
cases:3.01%
controls:0.00%
—
—
—
—
cases:5.34%
controls:0.72%
0
13
166
1637
—
—
5
0
161
1650
—
—
7
11
124
1518
More than one and less than three hours
ZXE10 [2001311401]
—
-1.0e+50
—
1.0e+50
1.0e+50
1.9e+00
1.4e+00
—
—
cases:0.00%
controls:1.21%
—
—
cases:4.22%
controls:0.00%
cases:5.45%
controls:0.00%
cases:5.63%
controls:0.85%
cases:7.63%
controls:2.09%
—
0
20
166
1630
—
7
0
159
1650
9
0
156
1649
9
14
151
1631
10
32
121
1497
etoricoxib; oral
M01AH05 [21603996]
2.3e-01
4.7e-01
—
—
1.9e+00
3.7e-01
-2.4e-01
cases:15.66%
controls:12.85%
cases:7.83%
controls:5.03%
—
—
—
—
cases:4.24%
controls:0.67%
cases:6.88%
controls:4.86%
cases:13.74%
controls:16.87%
26
212
140
1438
13
83
153
1567
—
—
7
11
158
1638
11
80
149
1565
18
258
113
1271
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
-2.0e-01
-1.7e-01
—
—
1.8e+00
6.6e-01
9.5e-02
cases:12.65%
controls:15.09%
cases:6.63%
controls:7.76%
—
—
—
—
cases:8.48%
controls:1.46%
cases:13.75%
controls:7.60%
cases:20.61%
controls:19.10%
21
249
145
1401
11
128
155
1522
—
—
14
24
151
1625
22
125
138
1520
27
292
104
1237
Intravenous general anesthesia
WX404 [2001310807]
—
—
—
1.0e+50
—
2.0e+00
1.8e+00
—
—
—
—
—
—
cases:4.22%
controls:0.00%
—
—
cases:3.13%
controls:0.43%
cases:7.63%
controls:1.31%
—
—
—
7
0
159
1650
—
5
7
155
1638
10
20
121
1509
Urgent procedure
ZXD05 [2001311386]
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.38%
controls:0.73%
—
—
—
—
—
—
—
7
12
153
1633
—
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
—
8.9e-01
—
1.0e+50
—
1.8e+00
8.4e-01
—
—
cases:3.61%
controls:1.52%
—
—
cases:10.24%
controls:0.00%
—
—
cases:9.38%
controls:1.64%
cases:11.45%
controls:5.30%
—
6
25
160
1625
—
17
0
149
1650
—
15
27
145
1618
15
81
116
1448
enoxaparin; parenteral
B01AB05 [21600976]
—
—
—
—
—
1.8e+00
7.0e-01
—
—
—
—
—
—
—
—
—
—
cases:5.63%
controls:0.97%
cases:6.11%
controls:3.14%
—
—
—
—
—
9
16
151
1629
8
48
123
1481
ibuprofen
R02AX02 [1588667]
-1.8e-01
-5.5e-02
8.5e-01
—
1.7e+00
5.2e-01
-3.1e-01
cases:34.34%
controls:38.42%
cases:16.27%
controls:17.03%
cases:4.82%
controls:2.12%
—
—
cases:9.70%
controls:1.88%
cases:24.38%
controls:16.11%
cases:32.06%
controls:39.24%
57
634
109
1016
27
281
139
1369
8
35
158
1615
—
16
31
149
1618
39
265
121
1380
42
600
89
929
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
-1.8e-01
-5.5e-02
8.5e-01
—
1.7e+00
5.2e-01
-3.1e-01
cases:34.34%
controls:38.42%
cases:16.27%
controls:17.03%
cases:4.82%
controls:2.12%
—
—
cases:9.70%
controls:1.88%
cases:24.38%
controls:16.11%
cases:32.06%
controls:39.24%
57
634
109
1016
27
281
139
1369
8
35
158
1615
—
16
31
149
1618
39
265
121
1380
42
600
89
929
Physiotherapy
R4110 [2001310233]
-2.2e-01
—
—
1.0e+50
—
1.7e+00
6.1e-01
cases:3.61%
controls:4.48%
—
—
—
—
cases:4.22%
controls:0.00%
—
—
cases:7.50%
controls:1.46%
cases:6.87%
controls:3.86%
6
74
160
1576
—
—
7
0
159
1650
—
12
24
148
1621
9
59
122
1470
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
—
—
—
—
—
1.7e+00
4.5e-01
—
—
—
—
—
—
—
—
—
—
cases:5.00%
controls:0.97%
cases:11.45%
controls:7.65%
—
—
—
—
—
8
16
152
1629
15
117
116
1412
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
2.1e-01
—
—
—
—
1.7e+00
1.3e-01
cases:4.82%
controls:3.94%
—
—
—
—
—
—
—
—
cases:10.00%
controls:2.07%
cases:9.92%
controls:8.83%
8
65
158
1585
—
—
—
—
16
34
144
1611
13
135
118
1394
Essential (primary) hypertension
I10 [45591453]
-2.5e-01
-4.4e-01
9.3e-01
—
1.7e+00
4.1e-01
-8.5e-01
cases:6.02%
controls:7.64%
cases:3.01%
controls:4.61%
cases:3.01%
controls:1.21%
—
—
cases:5.45%
controls:1.09%
cases:6.88%
controls:4.68%
cases:6.87%
controls:14.72%
10
126
156
1524
5
76
161
1574
5
20
161
1630
—
9
18
156
1631
11
77
149
1568
9
225
122
1304
Examination of eyes and vision
Z01.0 [45566391]
—
—
—
—
—
1.6e+00
3.6e-01
—
—
—
—
—
—
—
—
—
—
cases:5.00%
controls:1.03%
cases:3.82%
controls:2.68%
—
—
—
—
—
8
17
152
1628
5
41
126
1488
codeine and paracetamol
N02AJ06 [1123647]
1.8e-01
-2.8e-01
—
—
1.6e+00
7.4e-01
1.3e-01
cases:15.66%
controls:13.45%
cases:4.22%
controls:5.52%
—
—
—
—
cases:5.45%
controls:1.15%
cases:10.00%
controls:5.05%
cases:15.27%
controls:13.67%
26
222
140
1428
7
91
159
1559
—
—
9
19
156
1630
16
83
144
1562
20
209
111
1320
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
cases:8.75%
controls:1.95%
—
—
—
—
—
—
—
14
32
146
1613
—
Ophthalmology
18 [38004463]
-1.0e+00
-3.4e-01
—
—
-1.0e+50
1.5e+00
4.6e-01
cases:4.22%
controls:11.03%
cases:3.01%
controls:4.18%
—
—
—
—
cases:0.00%
controls:0.91%
cases:18.75%
controls:4.74%
cases:17.56%
controls:11.84%
7
182
159
1468
5
69
161
1581
—
—
0
15
165
1634
30
78
130
1567
23
181
108
1348
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
-7.0e-01
—
—
—
—
1.5e+00
-4.8e-01
cases:3.01%
controls:5.88%
—
—
—
—
—
—
—
—
cases:9.38%
controls:2.19%
cases:5.34%
controls:8.37%
5
97
161
1553
—
—
—
—
15
36
145
1609
7
128
124
1401
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
4.8e-01
—
—
—
—
1.5e+00
4.2e-01
cases:3.01%
controls:1.88%
—
—
—
—
—
—
—
—
cases:5.63%
controls:1.28%
cases:6.87%
controls:4.64%
5
31
161
1619
—
—
—
—
9
21
151
1624
9
71
122
1458
Internal Medicine
11 [38004456]
-4.0e-01
2.1e-01
1.3e+00
—
1.4e+00
1.5e+00
1.7e-01
cases:12.05%
controls:17.03%
cases:9.04%
controls:7.45%
cases:4.82%
controls:1.33%
—
—
cases:4.24%
controls:1.09%
cases:21.25%
controls:5.59%
cases:16.03%
controls:13.93%
20
281
146
1369
15
123
151
1527
8
22
158
1628
—
7
18
158
1631
34
92
126
1553
21
213
110
1316
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
—
—
—
—
—
1.8e+00
1.5e+00
—
—
—
—
—
—
—
—
—
—
cases:3.13%
controls:0.55%
cases:7.63%
controls:1.90%
—
—
—
—
—
5
9
155
1636
10
29
121
1500
Other specified special examinations
Z01.8 [45581003]
—
1.2e+00
—
—
—
1.7e+00
1.2e+00
—
—
cases:3.01%
controls:0.91%
—
—
—
—
—
—
cases:4.38%
controls:0.79%
cases:9.16%
controls:2.88%
—
5
15
161
1635
—
—
—
7
13
153
1632
12
44
119
1485
General anaesthesia
WX402 [2001310806]
—
—
—
1.0e+50
—
1.2e+00
1.2e+00
—
—
—
—
—
—
cases:7.23%
controls:0.00%
—
—
cases:4.38%
controls:1.34%
cases:12.98%
controls:4.25%
—
—
—
12
0
154
1650
—
7
22
153
1623
17
65
114
1464
General Practice
1 [38004446]
-6.1e-01
9.0e-02
1.5e+00
—
1.7e+00
9.0e-01
8.3e-01
cases:6.63%
controls:11.52%
cases:4.82%
controls:4.42%
cases:3.01%
controls:0.67%
—
—
cases:3.64%
controls:0.67%
cases:10.00%
controls:4.32%
cases:21.37%
controls:10.60%
11
190
155
1460
8
73
158
1577
5
11
161
1639
—
6
11
159
1638
16
71
144
1574
28
162
103
1367
clindamycin
D10AF01 [21602305]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
0
5
166
1645
—
—
—
—
0
11
131
1518
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
166
1637
—
—
—
—
—
—
Astrocytoma, NOS, of brain, NOS
9400/3-C71.9 [44500170]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:31.33%
controls:0.00%
—
—
—
—
—
—
—
—
—
52
0
114
1650
—
—
—
Trisomy 18 risk [Likelihood] in Fetus
43994-3 [3047352]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
0
5
160
1640
—
Continuous subcutaneous glucose monitoring
BEF00 [2001300849]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.72%
—
—
—
—
—
0
5
160
1640
0
11
131
1518
Psychological disorders other
P99 [2002000880]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
0
7
166
1643
—
—
—
—
—
0
7
131
1522
Varicose veins of lower extremities
I83 [45567245]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
—
Pain in throat
R07.0 [45592406]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
0
9
166
1641
0
5
166
1645
—
—
—
0
7
160
1638
—
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
-7.1e-01
—
—
—
-1.0e+50
—
-6.7e-01
cases:3.01%
controls:5.94%
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
cases:6.87%
controls:12.62%
5
98
161
1552
—
—
—
0
11
165
1638
—
9
193
122
1336
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.21%
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
0
20
166
1630
0
9
166
1641
—
—
—
0
6
160
1639
—
Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
7853-5 [3015635]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.67%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
0
11
166
1639
0
6
166
1644
—
—
—
—
0
13
131
1516
Erythrocytes [#/volume] in Cerebral spinal fluid
26454-9 [3027475]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
—
Gastro-oesophageal reflux disease
K21 [45586708]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.98%
—
—
—
—
—
0
5
160
1640
0
15
131
1514
hydrocortisone
S01CB03 [21603666]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
131
1524
tretinoin, combinations; ointment
D10AD51 [21602298]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
7
131
1522
Observation for suspected nervous system disorder
Z03.3 [45609903]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
7
131
1522
celecoxib; oral
M01AH01 [21603992]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
Additional procedure necessary for restorative treatment
SFC01 [2001310369]
-6.4e-02
—
—
—
—
—
7.8e-02
cases:5.42%
controls:5.76%
—
—
—
—
—
—
—
—
—
—
cases:4.58%
controls:4.25%
9
95
157
1555
—
—
—
—
—
6
65
125
1464
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
0
14
166
1636
—
—
—
0
9
160
1636
—
insulin aspart; parenteral
A10AD05 [21600733]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
cases:0.00%
controls:4.30%
cases:0.00%
controls:4.30%
cases:0.00%
controls:1.21%
—
—
—
—
—
—
cases:0.00%
controls:5.17%
0
71
166
1579
0
71
166
1579
0
20
166
1630
—
—
—
0
79
131
1450
Preparation for dental prosthetics
SPA02 [2001310460]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
131
1523
clindamycin; vaginal
G01AA10 [21602372]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
0
13
166
1637
—
—
—
—
—
dexamethasone and antiinfectives
S01CA01 [21603652]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.21%
cases:0.00%
controls:0.42%
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
0
20
166
1630
0
7
166
1643
—
—
—
0
11
160
1634
—
Orthopedic Surgery
20 [38004465]
3.0e-01
-2.6e-01
—
—
—
—
3.6e-01
cases:14.46%
controls:11.15%
cases:3.01%
controls:3.88%
—
—
—
—
—
—
—
—
cases:16.79%
controls:12.36%
24
184
142
1466
5
64
161
1586
—
—
—
—
22
189
109
1340
Follow-up examination after treatment of fracture
Z09.4 [45561611]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
166
1641
—
—
—
—
—
—
Obesity due to excess calories
E66.01 [2000501501]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
0
11
160
1634
—
Dysphasia and aphasia
R47.0 [45592421]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:3.13%
controls:0.00%
—
—
—
—
—
—
—
5
0
155
1645
—
Insulin-dependent diabetes mellitus - Diabetic retinopathy
H36.09*E10.3 [2000502327]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
0
7
166
1643
—
—
—
—
—
0
10
131
1519
Ultrasound examination of scrotum
KF8AE [2001306187]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
—
Breast sympt/compl female other
X21 [2002001306]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
0
5
166
1645
—
—
—
—
—
0
5
131
1524
Arthropathic psoriasis
L40.5 [45557703]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
131
1524
Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2865-4 [3015322]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
166
1644
—
—
—
—
—
—
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
-2.5e-01
-3.9e-01
—
—
-1.0e+50
-5.8e-01
-6.6e-01
cases:4.82%
controls:6.12%
cases:4.22%
controls:6.12%
—
—
—
—
cases:0.00%
controls:1.64%
cases:3.75%
controls:6.50%
cases:3.82%
controls:7.13%
8
101
158
1549
7
101
159
1549
—
—
0
27
165
1622
6
107
154
1538
5
109
126
1420
Hemoglobin.gastrointestinal [Presence] in Stool
2335-8 [3016251]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
11
131
1518
Photography of fundus of the eye or interpretation of photograph
SPAT1008 [2001700109]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
0
10
166
1640
0
7
166
1643
—
—
—
—
0
9
131
1520
Medical observation and evaluation for suspected diseases and conditions, ruled out
Z03 [45552058]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
0
7
166
1643
—
—
—
—
—
Urinary symptom/complaint other
U29 [2002001149]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
131
1524
Relationship problem with partner
Z12 [2002001468]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
7
131
1522
Melanocytic naevi
D22 [45595739]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
6
166
1644
—
—
—
—
—
Osmolality of Urine
2695-5 [3026782]
-3.1e-01
—
—
—
—
4.9e-01
—
cases:3.61%
controls:4.85%
—
—
—
—
—
—
—
—
cases:3.13%
controls:1.95%
—
—
6
80
160
1570
—
—
—
—
5
32
155
1613
—
Acute upper respiratory infections of multiple and unspecified sites
J06 [45601116]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
0
7
160
1638
—
alendronic acid; oral
M05BA04 [21604152]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
166
1640
—
—
—
—
—
—
Pure hypercholesterolaemia
E78.0 [45542771]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
0
9
166
1641
—
—
—
—
—
Other specified dermatitis
L30.8 [45581941]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
131
1523
tretinoin; ointment
D10AD01 [21602293]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
0
9
166
1641
0
7
166
1643
—
—
—
—
—
Nontoxic multinodular goitre
E04.2 [45576425]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
166
1644
—
—
—
—
—
—
Body temperature
8310-5 [3020891]
-1.0e+50
-1.0e+50
—
1.0e+50
1.0e+50
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.61%
—
—
cases:3.61%
controls:0.00%
cases:3.64%
controls:0.00%
—
—
—
—
0
5
166
1645
0
10
166
1640
—
6
0
160
1650
6
0
159
1649
—
—
Heartburn
R12 [45539318]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
0
9
166
1641
—
—
—
—
—
0
16
131
1513
Carboxyhemoglobin/Hemoglobin.total in Blood
20563-3 [3023081]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:4.22%
controls:0.00%
—
—
—
—
—
—
—
—
—
7
0
159
1650
—
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.94%
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
0
32
166
1618
0
10
166
1640
—
—
—
—
—
Demanding adjuvant cytostatic therapy
WB123 [2001310631]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
—
Gliadin peptide IgA Ab [Units/volume] in Serum by Immunoassay
63453-5 [40766183]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
9
166
1641
—
—
—
—
—
0
6
131
1523
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
10
166
1640
—
—
—
—
—
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
285 [2001600217]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
12
131
1517
diltiazem; oral
C08DB01 [21601771]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
—
X-ray mammography
HA1AA [2001303884]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
166
1641
—
—
—
—
—
—
encephalitis, tick borne, inactivated, whole virus
J07BA01 [21601331]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
0
10
160
1635
—
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
-7.1e-01
—
—
—
—
—
—
cases:3.01%
controls:5.94%
—
—
—
—
—
—
—
—
—
—
—
—
5
98
161
1552
—
—
—
—
—
—
HIV 1 RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification
10351-5 [3013180]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
8
131
1521
Other therapy enhancing rehabilitation
R4160 [2001310240]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
—
Atherosclerotic heart disease
I25.1 [45596196]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.96%
0
24
166
1626
—
—
—
—
—
0
30
131
1499
linagliptin; oral
A10BH05 [40251691]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.36%
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.59%
0
5
166
1645
0
7
166
1643
0
6
166
1644
—
—
0
7
160
1638
0
9
131
1520
Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum
7970-7 [3018387]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
8
131
1521
influenza, inactivated, split virus or surface antigen
J07BB02 [21601335]
-9.0e-02
2.9e-01
—
—
-1.0e+50
4.0e-01
-1.1e-02
cases:12.05%
controls:13.03%
cases:12.65%
controls:9.82%
—
—
—
—
cases:0.00%
controls:1.09%
cases:19.38%
controls:13.92%
cases:32.06%
controls:32.31%
20
215
146
1435
21
162
145
1488
—
—
0
18
165
1631
31
229
129
1416
42
494
89
1035
clozapine; oral, parenteral
N05AH02 [21604542]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
0
13
165
1636
—
—
Complicated extraction of tooth
EBA05 [2001301924]
3.6e-02
-1.0e+50
—
—
—
—
—
cases:3.01%
controls:2.91%
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
5
48
161
1602
0
11
166
1639
—
—
—
—
—
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
0
16
160
1629
—
Spirometry
127783003 [4133840]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
0
7
166
1643
—
—
—
—
—
0
5
131
1524
telmisartan; oral
C09CA07 [21601830]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
cases:0.00%
controls:1.18%
0
10
166
1640
—
—
—
—
0
11
160
1634
0
18
131
1511
Ultrasound examination of pregnancy (at 12. week of gestaion or later) including basic examination of fetus
MA2AE [2001306829]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
cases:0.00%
controls:1.34%
—
—
—
—
0
6
166
1644
—
—
0
22
160
1623
—
Redundant prepuce, phimosis and paraphimosis
N47 [45596870]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
0
5
166
1645
—
—
—
—
—
0
5
131
1524
other preparations, combinations; ointment
C05AX03 [21601631]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.46%
—
—
—
—
—
—
—
0
24
160
1621
—
Acceptance of acknowledgement of paternity of child born outside of marriage before the birth of the child at the maternity clinic. Paternity Act, Section 16.
SPAT1399 [2001700499]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
0
9
166
1641
—
—
—
—
—
Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay
89640-7 [1175715]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
8
131
1521
Gas and Carbon monoxide and Electrolytes panel - Arterial blood
93685-6 [1001509]
—
—
—
1.0e+50
1.0e+50
—
—
—
—
—
—
—
—
cases:12.65%
controls:0.00%
cases:7.88%
controls:0.00%
—
—
—
—
—
—
—
21
0
145
1650
13
0
152
1649
—
—
Sprain and strain of other and unspecified parts of knee
S83.6 [45579536]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
0
5
166
1645
—
—
—
—
0
11
131
1518
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
-1.0e+50
—
—
—
—
—
5.5e-01
cases:0.00%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
cases:5.34%
controls:3.14%
0
17
166
1633
—
—
—
—
—
7
48
124
1481
Alveolitis of jaws
K10.3 [45591576]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
0
6
166
1644
—
—
—
0
5
160
1640
—
insulin detemir; parenteral
A10AE05 [21600740]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:2.97%
cases:0.00%
controls:2.48%
cases:0.00%
controls:0.61%
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:1.95%
cases:0.00%
controls:2.55%
0
49
166
1601
0
41
166
1609
0
10
166
1640
—
0
10
165
1639
0
32
160
1613
0
39
131
1490
Wheezing
R06.2 [45548946]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
0
6
166
1644
—
—
—
—
—
0
5
131
1524
Supervision of pregnancy with history of infertility
Z35.0 [45600322]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
166
1642
—
—
—
—
—
—
Other rheumatoid arthritis
M06 [45596441]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
—
Follow-up examination after surgery for other conditions
Z09.0 [45576131]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
0
9
166
1641
—
—
—
—
—
0
10
131
1519
Achilles tendinitis
M76.6 [45596682]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
131
1524
Hyperemia of pulp
K04.00 [2000502702]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
6
166
1644
—
—
—
—
—
Other somatoform disorders
F45.8 [45600750]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
—
0
13
166
1637
—
—
—
—
—
Monitoring the use of the aid
R5140 [2001310249]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
0
8
160
1637
—
Extractable nuclear Ab [Units/volume] in Serum
30342-0 [3015171]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
14
131
1515
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
-1.3e-01
1.3e-02
6.9e-01
—
—
-3.0e-01
-2.8e-01
cases:6.63%
controls:7.45%
cases:10.24%
controls:10.12%
cases:4.82%
controls:2.48%
—
—
—
—
cases:10.00%
controls:13.07%
cases:22.90%
controls:28.12%
11
123
155
1527
17
167
149
1483
8
41
158
1609
—
—
16
215
144
1430
30
430
101
1099
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
-1.8e-01
1.9e-01
1.1e+00
—
—
-3.4e-02
-2.9e-01
cases:24.10%
controls:27.45%
cases:18.07%
controls:15.39%
cases:4.82%
controls:1.70%
—
—
—
—
cases:15.00%
controls:15.44%
cases:30.53%
controls:36.95%
40
453
126
1197
30
254
136
1396
8
28
158
1622
—
—
24
254
136
1391
40
565
91
964
Kappa light chains.free [Mass/volume] in Serum
36916-5 [3034860]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
0
5
166
1645
—
—
—
—
—
0
7
131
1522
Lysozyme [Mass/volume] in Serum or Plasma
2589-0 [3012110]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.72%
—
—
—
—
—
0
5
160
1640
0
11
131
1518
Photocoagulation of retina
CKC12 [2001301394]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
0
15
131
1514
Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
166
1643
—
—
—
—
—
—
Fracture of tooth
S02.5 [45549037]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
166
1643
—
—
—
—
—
—
Unspecified lump in breast
N63 [45601743]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.31%
0
7
166
1643
0
5
166
1645
—
—
—
—
0
20
131
1509
Lumbar spine extensive MRI examination with high intensity magnet
NA3CG [2001307039]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
—
Opening and preparing the root canals, extremely complicated
SGA04 [2001310382]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.70%
—
0
9
166
1641
—
—
—
—
0
26
131
1503
Spinal stenosis
M48.0 [45557888]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.98%
—
0
9
166
1641
—
—
—
0
6
160
1639
0
15
131
1514
Sneezing/nasal congestion
R07 [2002000888]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
166
1631
—
—
—
—
—
—
Chalazion
H00.1 [45542919]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
131
1524
Malignant neoplasm: Frontal lobe
C71.1 [45557008]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:21.25%
controls:0.00%
—
—
—
—
—
—
—
34
0
126
1645
—
Intubation
WX704 [2001310820]
-1.0e+50
—
—
1.0e+50
—
—
1.5e+00
cases:0.00%
controls:0.42%
—
—
—
—
cases:3.01%
controls:0.00%
—
—
—
—
cases:5.34%
controls:1.24%
0
7
166
1643
—
—
5
0
161
1650
—
—
7
19
124
1510
Helicobacter pylori Ag [Presence] in Stool
31843-6 [3013139]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:1.64%
—
—
—
—
—
0
5
160
1640
0
25
131
1504
Other reactions to severe stress
F43.8 [45552483]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
166
1643
—
—
—
—
—
—
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
cases:3.13%
controls:0.97%
—
—
—
—
—
—
—
5
16
155
1629
—
Urticaria, unspecified
L50.9 [45562541]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
—
Shoulder lesion, unspecified
M75.9 [45557986]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
0
6
166
1644
—
—
—
—
—
0
12
131
1517
Physiotherapist
Z3226 [2001311560]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.58%
controls:0.92%
—
—
—
—
—
—
6
14
125
1515
Arthrosis, unspecified
M19.9 [45543488]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
131
1523
Verruca simplex
B07.9 [2000500357]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
166
1642
—
—
—
—
—
—
Stress fracture, not elsewhere classified
M84.3 [45596702]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
131
1524
Contusion of other and unspecified parts of lower leg
S80.1 [45550389]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
7
131
1522
quetiapine; oral
N05AH04 [21604544]
-4.7e-01
—
—
—
—
4.2e-01
1.1e-01
cases:3.01%
controls:4.73%
—
—
—
—
—
—
—
—
cases:5.00%
controls:3.34%
cases:6.11%
controls:5.49%
5
78
161
1572
—
—
—
—
8
55
152
1590
8
84
123
1445
Neoplasm of uncertain or unknown behaviour: Brain, unspecified
D43.2 [45566690]
—
—
1.0e+50
—
—
—
—
—
—
—
—
cases:3.01%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
5
0
161
1650
—
—
—
—
Hepatitis E virus Ab [Presence] in Serum
13294-4 [3006922]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
7
131
1522
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
-3.8e-01
—
-1.0e+50
—
—
—
-7.6e-01
cases:3.61%
controls:5.21%
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:4.58%
controls:9.35%
6
86
160
1564
—
0
6
166
1644
—
—
—
6
143
125
1386
montelukast; oral
R03DC03 [21603356]
—
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:0.36%
—
—
—
—
cases:0.00%
controls:1.52%
cases:0.00%
controls:3.14%
—
0
16
166
1634
0
6
166
1644
—
—
0
25
160
1620
0
48
131
1481
Unspecified injury of ankle and foot
S99.9 [45541238]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
166
1644
—
—
—
—
—
—
Chronic ischaemic heart disease, unspecified
I25.9 [45552784]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
166
1641
—
—
—
—
—
—
Occupatioal Medicine
901 [44777713]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.78%
—
—
—
—
—
—
0
12
131
1517
Anaemia, unspecified
D64.9 [45600610]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
—
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.9e-01
-2.7e-02
—
—
—
2.4e-01
2.5e-01
cases:8.43%
controls:7.09%
cases:3.01%
controls:3.09%
—
—
—
—
—
—
cases:3.75%
controls:2.98%
cases:9.92%
controls:7.91%
14
117
152
1533
5
51
161
1599
—
—
—
6
49
154
1596
13
121
118
1408
Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
29257-3 [3002482]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
8
131
1521
Appendectomy
JEA00 [2001304802]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
166
1644
—
—
—
—
—
—
fluticasone furoate
R03BA09 [45893496]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
0
21
166
1629
0
5
166
1645
—
—
—
—
Systematic individual therapy, cognitive-behavioural
IDY03 [2001304164]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
Contusion of other parts of wrist and hand
S60.2 [45602941]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
0
7
166
1643
—
—
—
—
—
0
10
131
1519
Otitis media, unspecified
H66.9 [45547965]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.91%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
0
15
166
1635
0
5
166
1645
—
—
—
0
5
160
1640
—
losartan and diuretics
C09DA01 [21601834]
1.2e+00
—
—
—
—
—
—
cases:3.01%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
—
—
5
16
161
1634
—
—
—
—
—
—
Orchitis, epididymitis and epididymo-orchitis without abscess
N45.9 [45548671]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
166
1645
—
—
—
—
—
—
Irrigation or wax removal of outer auditory canal
SPAT1033 [2001700134]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
cases:0.00%
controls:1.05%
—
—
—
—
—
0
9
160
1636
0
16
131
1513
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
4.6e-02
1.8e-01
1.4e+00
—
—
-1.1e-01
-5.1e-01
cases:9.04%
controls:8.67%
cases:6.02%
controls:5.09%
cases:3.01%
controls:0.73%
—
—
—
—
cases:5.63%
controls:6.26%
cases:11.45%
controls:17.66%
15
143
151
1507
10
84
156
1566
5
12
161
1638
—
—
9
103
151
1542
15
270
116
1259
Smooth muscle Ab [Titer] in Serum
8095-2 [3007566]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.55%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
0
9
166
1641
0
5
166
1645
—
—
—
—
0
17
131
1512
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.27%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
0
21
166
1629
0
6
166
1644
—
—
—
—
—
Periodontal treatment, very brief
SDA01 [2001310326]
2.4e-01
—
—
—
—
—
—
cases:4.82%
controls:3.82%
—
—
—
—
—
—
—
—
—
—
—
—
8
63
158
1587
—
—
—
—
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
0
7
166
1643
—
—
—
—
—
Specialised imaging for glaucoma
CS5Z4 [2001301479]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
131
1524
Microscopic observation [Identifier] in Vaginal fluid by Gram stain
14361-0 [3000855]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
166
1644
—
—
—
—
—
—
Lactate [Moles/volume] in Blood
32693-4 [3047181]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:4.22%
controls:0.00%
—
—
—
—
—
—
—
—
—
7
0
159
1650
—
—
—
Opiates [Presence] in Urine
3879-4 [3027008]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
0
11
160
1634
—
Impetigo [any organism] [any site]
L01.0 [45572243]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
5
131
1524

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
97
102
21.47
92.51
1.4
1.3
—
—
—
0
0
87
128
13.18
63.42
5.9
13.4
0.60
1.62
mmol/l
2.16
69
104
87
129
13.07
63.01
6.0
13.3
7.41
7.42
ph
0.29
59
74
64
80
12.39
51.62
4.8
6.8
23.91
25.36
mmol/l
2.62
64
80
131
608
6.48
25.07
7.4
8.0
1.20
1.21
mmol/l
1.07
119
527
106
469
4.49
19.97
2.3
2.3
—
—
—
0
0
111
541
4.17
17.49
3.4
1.9
—
—
—
0
0
123
666
4.27
16.14
2.9
2.9
—
—
estimate
—
0
0
26
42
7.15
16.00
2.0
1.5
—
—
—
0
0
39
110
4.33
12.93
6.9
8.9
—
—
—
0
0
93
470
3.23
12.49
10.7
6.8
—
—
—
0
0
22
21
11.89
12.19
2.0
1.2
—
—
—
0
0
97
513
3.14
11.85
4.0
11.1
1.01
1.17
inr
10.07
79
426
132
844
3.75
11.53
18.0
10.6
3.43
3.98
e9/l
2.79
114
742
23
48
5.40
10.85
1.9
1.3
68.06
17.64
e6/l
0.63
16
33
23
48
5.40
10.85
2.0
1.4
975.06
27.31
e6/l
0.49
16
35
82
418
2.90
10.33
9.3
3.6
2.38
2.35
mmol/l
1.62
77
381
25
60
4.73
10.04
5.4
13.9
—
—
—
0
0
117
746
2.93
9.26
10.8
6.9
0.53
0.55
e9/l
0.71
99
658
117
748
2.91
9.17
10.7
6.9
0.03
0.04
e9/l
4.87
98
659
119
776
2.88
8.83
10.9
7.4
0.12
0.19
e9/l
8.19
102
693
116
770
2.68
7.90
10.9
7.0
1.50
1.84
e9/l
5.38
98
692
83
472
2.52
7.85
1.3
1.6
—
—
—
0
0
109
704
2.60
7.83
11.0
6.9
60.16
57.01
%
1.75
109
688
89
540
2.40
7.09
4.5
5.2
36.96
36.82
g/l
0.08
84
517
113
1402
0.39
6.81
3.4
4.4
4.91
4.70
mmol/l
1.32
103
1333
113
1398
0.40
6.56
3.4
4.4
1.40
1.41
mmol/l
0.13
102
1324
117
1414
0.42
5.79
3.5
4.8
3.04
2.83
mmol/l
1.73
105
1340
66
379
2.23
5.69
2.8
3.7
7.40
7.40
ph
0.31
40
273
9
8
11.80
5.35
3.6
6.0
9.33
9.88
%
—
9
8
9
8
11.80
5.35
1.8
3.0
36.56
39.38
%
—
9
8
59
331
2.21
5.33
3.5
4.5
—
—
—
0
0
93
632
2.07
5.01
15.7
11.0
0.00
0.00
e9/l
0.37
70
520
12
23
5.54
4.55
1.8
1.5
—
—
—
0
0
110
1327
0.49
4.20
3.1
3.7
1.35
1.28
mmol/l
0.43
99
1245
106
1278
0.53
3.62
3.9
5.1
36.15
38.01
mmol/mol
2.65
95
1224
111
1309
0.54
3.24
4.2
4.2
5.49
5.77
mmol/l
3.02
104
1226
69
480
1.75
3.02
2.7
3.1
13.33
29.45
ng/l
1.64
46
277
45
666
0.56
2.85
2.1
2.7
—
—
—
0
0
59
408
1.69
2.56
9.5
6.6
—
—
—
0
0
0
61
0.00
2.29
0.0
1.2
—
—
—
0
0
52
367
1.61
2.03
4.7
3.1
—
—
—
0
0
19
333
0.52
2.00
3.3
3.6
26.22
64.09
mg/l
1.44
13
221
8
185
0.40
1.95
1.0
1.3
—
—
—
0
0
20
342
0.53
1.95
3.6
4.3
4.82
9.35
mg/mmol
0.60
12
220
7
22
3.27
1.90
3.1
2.4
2.27
2.53
mmol/l
—
7
15
7
22
3.27
1.90
3.1
2.4
5.19
4.95
kpa
—
7
22
7
22
3.27
1.90
3.1
2.4
8.81
8.86
kpa
—
7
22
5
12
4.26
1.83
1.4
1.3
93.04
91.07
%
—
5
12
151
1586
0.47
1.81
40.7
20.6
135.83
138.73
g/l
1.79
151
1575
48
342
1.57
1.78
2.4
2.6
—
—
—
0
0
151
1585
0.48
1.76
39.6
20.5
4.51
4.61
e12/l
1.81
151
1557
151
1585
0.48
1.76
40.4
20.9
40.44
41.37
%
2.24
151
1572
151
1585
0.48
1.76
39.5
20.6
6.50
6.59
e9/l
0.20
151
1557
151
1585
0.48
1.76
39.5
20.5
30.50
30.25
pg
1.11
151
1574
0
46
0.00
1.73
0.0
3.0
—
874.76
—
0
38
151
1584
0.48
1.70
39.7
20.5
90.69
90.32
fl
0.52
151
1573
151
1583
0.49
1.65
39.5
20.6
246.44
252.15
e9/l
0.31
151
1561
19
107
1.88
1.63
1.2
1.2
—
27.06
—
0
7
6
20
3.07
1.59
1.3
2.5
19.20
17.02
%
—
6
20
6
22
2.79
1.45
2.8
3.1
—
—
—
0
0
151
1406
1.82
1.40
25.4
14.3
3.90
3.94
mmol/l
1.55
151
1375
151
1407
1.81
1.38
26.1
14.2
139.23
139.72
mmol/l
1.30
151
1381
31
213
1.56
1.33
2.8
2.6
4.28
2.62
e6/l
0.25
16
92
35
248
1.52
1.31
2.1
2.9
28.27
703.13
ng/l
0.82
15
153
20
124
1.70
1.28
4.3
4.2
1.60
0.91
%
—
10
34
19
294
0.60
1.27
1.7
1.5
—
—
—
0
0
48
608
0.70
1.23
3.1
3.1
6.34
6.20
ph
0.36
32
347
29
403
0.66
1.21
3.1
3.5
0.00
0.00
estimate
—
10
151
120
1308
0.70
1.18
4.3
5.1
1.57
1.75
mu/l
1.52
113
1230
0
33
0.00
1.17
0.0
3.2
—
61.58
—
0
33
10
180
0.53
1.15
1.1
1.3
—
—
—
0
0
7
32
2.24
1.09
3.1
3.3
7.43
7.41
ph
—
7
32
26
361
0.67
1.08
1.1
1.4
1.73
2.34
g/l
2.50
12
232
9
160
0.54
1.04
1.1
1.5
—
—
—
0
0
15
232
0.61
1.01
2.2
2.8
0.61
0.77
ug/l
—
8
126
27
192
1.49
1.01
1.3
1.6
—
—
—
0
0
61
723
0.75
0.97
2.5
3.1
89.21
92.79
ug/l
0.09
55
692
21
296
0.67
0.94
1.3
1.9
—
—
—
0
0
63
740
0.76
0.92
3.3
3.5
0.00
0.00
estimate
-0.00
12
156
6
30
2.04
0.88
2.5
19.6
—
—
—
0
0
10
162
0.59
0.82
1.4
1.5
—
—
—
0
0
97
868
1.28
0.82
3.9
4.3
—
56.92
—
0
13
65
751
0.78
0.81
3.3
3.6
0.00
0.00
estimate
-0.00
12
146
5
96
0.51
0.81
1.0
1.1
—
—
—
0
0
46
374
1.32
0.80
2.5
2.7
0.14
0.18
e6/l
0.26
32
270
65
747
0.79
0.76
3.1
3.5
0.00
0.00
estimate
-0.00
12
156
17
117
1.50
0.75
4.0
4.3
0.14
0.23
%
—
7
26
7
117
0.58
0.71
1.1
1.1
—
—
—
0
0
7
41
1.74
0.71
1.6
1.1
—
—
—
0
0
7
41
1.74
0.71
1.6
1.1
—
—
—
0
0
36
442
0.76
0.70
3.2
2.8
0.00
0.01
estimate
—
10
129
10
61
1.68
0.70
2.4
1.8
20.40
20.74
s
—
10
53
12
178
0.65
0.69
1.3
1.2
—
—
—
0
0
0
21
0.00
0.60
0.0
1.2
—
—
—
0
0
0
22
0.00
0.60
0.0
1.4
—
—
—
0
0
8
122
0.64
0.57
2.0
1.7
—
—
—
0
0
43
363
1.25
0.56
7.0
4.7
—
—
—
0
0
12
82
1.50
0.56
1.8
1.9
—
—
—
0
0
149
1436
1.37
0.54
23.7
13.4
19.59
21.91
mg/l
0.55
141
1148
50
572
0.82
0.52
3.3
3.2
0.00
0.00
estimate
-0.00
11
137
7
46
1.54
0.49
2.1
1.6
0.16
0.39
nmol/l
—
7
41
8
116
0.67
0.47
2.0
1.7
—
—
—
0
0
5
84
0.58
0.47
1.0
1.2
—
—
—
0
0
14
185
0.73
0.46
1.1
2.3
—
—
—
0
0
18
139
1.33
0.46
1.1
1.2
—
—
—
0
0
43
372
1.21
0.45
2.2
2.6
—
—
estimate
—
0
0
43
492
0.83
0.45
1.8
2.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
2.2
—
—
—
0
0
101
1070
0.86
0.40
3.8
4.4
14.23
14.58
pmol/l
0.73
94
1003
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
0
19
0.00
0.39
0.0
1.9
—
11.58
—
0
19
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
15
116
1.32
0.38
4.1
4.2
1.10
0.83
%
—
5
29
9
69
1.32
0.38
1.3
3.5
7.44
7.41
ph
—
9
57
121
1262
0.85
0.37
32.6
16.5
13.34
13.34
%
0.01
121
1251
9
123
0.72
0.36
1.9
1.7
—
—
—
0
0
9
124
0.71
0.36
1.9
1.7
—
—
—
0
0
9
124
0.71
0.36
1.8
1.7
—
—
—
0
0
146
1496
0.80
0.34
20.6
11.5
—
—
—
0
0
6
46
1.32
0.33
1.5
3.8
—
—
—
0
0
15
120
1.27
0.31
4.1
4.6
0.00
0.07
%
—
5
27
44
395
1.16
0.31
1.5
1.8
—
—
—
0
0
9
117
0.76
0.28
3.0
3.2
—
—
—
0
0
29
328
0.86
0.26
2.8
3.4
1.02
1.02
kg/l
0.66
19
217
9
72
1.26
0.26
1.1
1.2
—
—
—
0
0
48
441
1.12
0.24
2.6
2.8
22.38
195.19
e6/l
0.61
34
336
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
2.8
—
1.03
—
0
8
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
75.08
—
0
13
0
13
0.00
0.21
0.0
1.1
—
147.58
—
0
13
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
5.2
—
2.86
—
0
14
0
14
0.00
0.20
0.0
3.4
—
—
—
0
0
19
166
1.16
0.19
1.8
1.6
1267.80
1184.94
nmol/l
—
10
127
11
92
1.21
0.16
2.3
4.1
62.86
75.63
e9/l
—
5
63
6
76
0.78
0.16
1.0
1.1
1.43
1.48
g/l
—
6
76
6
77
0.77
0.16
1.0
1.1
0.78
0.90
g/l
—
6
77
50
530
0.92
0.16
1.7
1.9
93.19
101.00
pmol/l
0.61
27
269
6
78
0.76
0.16
1.2
1.6
—
—
—
0
0
6
80
0.74
0.16
1.2
1.7
—
—
—
0
0
9
80
1.13
0.15
1.7
2.1
8.77
6.25
ug/l
—
9
71
7
85
0.82
0.15
3.9
3.6
67.29
79.31
ng/l
—
7
76
30
276
1.11
0.15
1.4
1.7
—
—
—
0
0
150
1516
0.89
0.11
20.7
10.9
29.21
28.34
u/l
0.21
150
1494
30
320
0.92
0.11
2.0
2.0
1.84
2.71
mg/l
3.15
24
279
31
330
0.93
0.10
1.5
1.8
1.19
1.22
mg/l
0.02
22
252
6
53
1.14
0.09
1.0
1.1
—
—
—
0
0
6
73
0.82
0.08
1.3
3.1
25.33
24.26
mmol/l
—
6
73
50
518
0.95
0.07
3.1
3.5
46.92
60.62
e6/l
0.13
34
357
36
346
1.05
0.06
1.4
1.5
17.37
20.43
nmol/l
0.75
31
303
11
120
0.91
0.05
1.6
3.6
6.05
5.72
kpa
0.62
11
115
17
179
0.94
0.03
2.1
2.9
10.42
7.39
umol/l
0.18
12
162
16
168
0.95
0.02
1.3
1.7
—
—
—
0
0
151
1516
0.96
0.00
30.4
15.9
69.56
75.41
umol/l
3.57
151
1500
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
28.57
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
55
0.91
-0.00
1.2
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.5
—
2.67
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
6.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
1999.00
—
0
5
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
9.7
—
39.35
—
0
6
0
6
0.00
-0.00
0.0
6.2
—
10.49
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
0.00
—
0
5
0
6
0.00
-0.00
0.0
1.5
—
57.00
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
11.82
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
185.67
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: HLP_C3_ASTROCYTOMA – Brain astrocytoma, helper endpoint

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).